Baudax Bio (BXRXQ) 10-Q 8 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 02, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	Baudax Bio, Inc.
Entity Central Index Key	0001780097
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		20,003,745
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Trading Symbol	BXRX
Entity File Number	001-39101
Entity Tax Identification Number	47-4639500
Entity Address, Address Line One	490 Lapp Road
Entity Address, City or Town	Malvern
City Area Code	484
Local Phone Number	395-2440
Entity Address, Postal Zip Code	19355
Entity Address, State or Province	PA
Entity Incorporation, State or Country Code	PA
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, par value $0.01

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,647	$ 15,891
Accounts receivable, net	313	542
Inventory	4,477	5,002
Prepaid expenses and other current assets	832	2,059
Total current assets	11,269	23,494
Property and equipment, net	1,239	5,015
Intangible assets, net	2,000	21,678
Goodwill	2,127	2,127
Other long-term assets	875	963
Total assets	17,510	53,277
Current liabilities:
Accounts payable	3,609	1,468
Accrued expenses and other current liabilities	3,319	5,540
Current portion of long-term debt, net	5,911	2,222
Current portion of contingent consideration	8,436	6,416
Total current liabilities	21,275	15,646
Long-term debt, net	2,175	6,309
Long-term portion of contingent consideration	12,972	17,446
Other long-term liabilities	628	650
Total liabilities	37,050	40,051
Commitments and contingencies (Note 12)
Shareholders' (deficit) equity:
Preferred stock, $0.01 par value. Authorized, 10,000,000 shares; issued and outstanding, 20,003.745 shares at September 30, 2022 (all of which shares were issued on October 3, 2022 pursuant to a stock dividend) and 8289 shares at December 31, 2021	0	0
Common stock, $0.01 par value. Authorized, 190,000,000 shares; issued and outstanding, 20,003,745 shares at September 30 2022 and 2,807,239 shares at December 31, 2021	200	28
Additional paid-in capital	161,914	145,287
Accumulated deficit	(181,654)	(132,089)
Total shareholders' (deficit) equity	(19,540)	13,226
Total liabilities and shareholders' (deficit) equity	$ 17,510	$ 53,277

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	20,003.745	8,289
Preferred stock, shares outstanding	20,003.745	8,289
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	190,000,000	190,000,000
Common stock, shares issued	20,003,745	2,807,239
Common stock, shares outstanding	20,003,745	2,807,239

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue, net	$ 238	$ 281	$ 959	$ 680
Operating expenses:
Cost of sales	1,208	462	2,217	1,869
Research and development	645	658	2,850	2,623
Selling, general and administrative	3,808	11,074	22,027	33,770
Amortization of intangible assets	644	644	1,932	1,932
Change in warrant valuation	(1)	(6)	(7)	(47)
Change in contingent consideration valuation	1,222	3,829	(1,254)	9,551
Loss on impairment of property and equipment	3,662	0	3,662	0
Loss on impairment of intangible asset	17,746	0	17,746	0
Total operating expenses	28,934	16,661	49,173	49,698
Operating loss	(28,696)	(16,380)	(48,214)	(49,018)
Other expense:
Other expense, net	(509)	(582)	(1,331)	(185)
Net loss	$ (29,205)	$ (16,962)	$ (49,545)	$ (49,203)
Per share information:
Net loss per share of common stock, basic	$ (2.47)	$ (7.03)	$ (6.45)	$ (23.29)
Net loss per share of common stock, diluted	$ (2.47)	$ (7.03)	$ (6.45)	$ (23.29)
Weighted average common shares outstanding, basic	11,836,122	2,411,433	7,685,398	2,112,247
Weighted average common shares outstanding, diluted	11,836,122	2,411,433	7,685,398	2,112,247

Consolidated Statements of Shar

Consolidated Statements of Shareholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Total	Registered Direct Offerings	Public Offerings	Recro	Preferred Stock	Common Stock	Common Stock Registered Direct Offerings	Common Stock Public Offerings	Additional Paid in Capital	Additional Paid in Capital Registered Direct Offerings	Additional Paid in Capital Public Offerings	Additional Paid in Capital Recro	Accumulated Deficit
Balance at Dec. 31, 2020	$ (14,799)					$ 14			$ 97,507				$ (112,320)
Balance, Shares at Dec. 31, 2020					0	1,391,099
Stock-based compensation expense	975			$ 1,201					975			$ 1,201
Issuance of common stock		$ 16,427					$ 3			$ 16,424
Issuance of common stock, Shares							314,286
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes	(41)								(41)
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares						1,205
Exercise of warrants	12,155					$ 3			12,152
Exercise of warrants, Shares						297,484
Net loss	(16,912)												(16,912)
Balance at Mar. 31, 2021	(994)					$ 20			128,218				(129,232)
Balance, Shares at Mar. 31, 2021					0	2,004,074
Balance at Dec. 31, 2020	(14,799)					$ 14			97,507				(112,320)
Balance, Shares at Dec. 31, 2020					0	1,391,099
Net loss	(49,203)
Balance at Sep. 30, 2021	(20,728)					$ 24			140,771				(161,523)
Balance, Shares at Sep. 30, 2021						2,412,095
Balance at Mar. 31, 2021	(994)					$ 20			128,218				(129,232)
Balance, Shares at Mar. 31, 2021					0	2,004,074
Stock-based compensation expense	854								854
Issuance of common stock	10,901					$ 4			10,897
Issuance of common stock, Shares						400,815
Exercise of warrants	5					$ 0			5
Exercise of warrants, Shares						2,917
Net loss	(15,329)												(15,329)
Balance at Jun. 30, 2021	(4,573)					$ 24			139,964				(144,561)
Balance, Shares at Jun. 30, 2021					0	2,407,806
Stock-based compensation expense	874								874
Issuance of common stock	(38)								(38)
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes	(29)								(29)
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares						4,289
Net loss	(16,962)												(16,962)
Balance at Sep. 30, 2021	(20,728)					$ 24			140,771				(161,523)
Balance, Shares at Sep. 30, 2021						2,412,095
Balance at Dec. 31, 2021	13,226					$ 28			145,287				(132,089)
Balance, Shares at Dec. 31, 2021					8,289	2,807,239
Stock-based compensation expense	521								521
Issuance of common stock		(13)	$ 8,819					$ 35		(13)	$ 8,784
Issuance of common stock, Shares								3,508,772
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes	(1)								(1)
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares						2,234
Conversion of preferred stock					(8,289)	94,734
Conversion of preferred stock Amount								$ 1	(1)
Net loss	(12,809)												(12,809)
Balance at Mar. 31, 2022	9,743					$ 64			154,577				(144,898)
Balance, Shares at Mar. 31, 2022					0	6,412,979
Balance at Dec. 31, 2021	13,226					$ 28			145,287				(132,089)
Balance, Shares at Dec. 31, 2021					8,289	2,807,239
Net loss	(49,545)
Balance at Sep. 30, 2022	(19,540)					$ 200			161,914				(181,654)
Balance, Shares at Sep. 30, 2022					20,003.745	20,003,745
Balance at Mar. 31, 2022	9,743					$ 64			154,577				(144,898)
Balance, Shares at Mar. 31, 2022					0	6,412,979
Stock-based compensation expense	325								325
Issuance of common stock		$ 1,720	$ (28)				$ 16			$ 1,704	$ (28)
Issuance of common stock, Shares							1,646,091
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes	1					$ 9,783		$ 1
Net loss	(7,531)												(7,531)
Balance at Jun. 30, 2022	4,230					$ 81			156,578				$ (152,429)
Balance, Shares at Jun. 30, 2022					0	8,068,853
Stock-based compensation expense	301								301
Issuance of common stock	5,065					$ 118			4,947
Issuance of common stock, Shares						11,819,172
Issuance of shares pursuant to vesting of restricted stock units, net of shares withheld for income taxes, Shares						720
Exercise of warrants	69					$ 1			$ 68
Exercise of warrants, Shares						115,000
Stock Dividend					20,003.745				20				(20)
Net loss	(29,205)												$ (29,205)
Balance at Sep. 30, 2022	$ (19,540)					$ 200			$ 161,914				$ (181,654)
Balance, Shares at Sep. 30, 2022					20,003.745	20,003,745

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (49,545)	$ (49,203)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,172	4,132
Non-cash interest expense	652	673
Depreciation expense	125	195
Amortization	1,932	1,932
Non-cash loss on retirement of fixed assets	8	0
Gain on extinguishment of debt	0	(1,553)
Change in warrant valuation	(7)	(47)
Change in contingent consideration valuation	(1,254)	9,551
Loss on impairment of property and equipment	3,662	0
Loss on impairment of intangible asset	17,746	0
Write off of inventory	843	202
Changes in operating assets and liabilities:
Inventory	(318)	(1,534)
Prepaid expenses and other assets	1,330	1,474
Accounts receivable	229	(371)
Accounts payable, accrued expenses and other liabilities	(585)	(2,075)
Net cash used in operating activities	(24,010)	(36,624)
Cash flows from investing activities:
Purchase of property and equipment	(20)	(76)
Purchase of short-term investments	0	(19,641)
Proceeds from maturity of short-term investments	0	9,500
Net cash used in investing activities	(20)	(10,217)
Cash flows from financing activities:
Proceeds from public offering, net of transaction costs	14,270	0
Proceeds from registered direct offerings, net of transaction costs	1,762	27,059
Payments on long-term debt	(1,112)	0
Proceeds from warrant exercises	69	12,155
Payment of contingent consideration	(1,200)	(7,869)
Payments of withholdings on shares withheld for income taxes	(3)	(74)
Net cash provided by financing activities	13,786	31,271
Net decrease in cash and cash equivalents	(10,244)	(15,570)
Cash and cash equivalents, beginning of period	15,891	30,342
Cash and cash equivalents, end of period	5,647	14,772
Supplemental disclosure of cash flow information:
Right-of-use assets acquired	0	575
Offering costs included in accounts payable and accrued expenses	$ 493	$ 0

Background

Background	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	(1) Background Business Baudax Bio, Inc. (“Baudax Bio” or the “Company”) is a pharmaceutical company primarily focused on innovative products for hospital and related settings. Baudax Bio believes it can bring valuable therapeutic options to patients, prescribers and payers, such as its lead product, ANJESO ® (meloxicam) injection, to the hospital and related markets. Baudax Bio launched ANJESO, which is indicated for the management of moderate to severe pain, in 2020. ANJESO is currently approved for use within numerous hospitals, ambulatory care centers and the Department of Veterans Affairs, the Department of Defense, Indian Health Service, 340B covered entities, and multiple state Medicaid programs. The Company has determined that it operates in a single segment involved in innovative products for hospital and related settings. The Separation Pursuant to the Separation Agreement between Societal CDMO, Inc. (“Societal CDMO”), formerly Recro Pharma, Inc., and Baudax Bio, Societal CDMO transferred the assets, liabilities, and operations of its Acute Care business to the Company (the “Separation”) and, on November 21, 2019, the distribution date, each Societal CDMO shareholder received one share of the Company’s common stock for every two and one-half shares of Societal CDMO common stock held of record at the close of business on November 15, 2019, the record date for the distribution (the “Distribution”). Following the Distribution and Separation, Baudax Bio operates as a separate, independent company. Reverse Stock Split On February 16, 2022, the Company effected a reverse split of shares of the Company’s common stock on a 1-for-35 basis (the “Reverse Stock Split”). All issued and outstanding shares of common stock, warrants, common stock options, and unvested restricted stock units and the related per share amounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. The par value and authorized shares of common stock were not adjusted as a result of the Reverse Stock Split. Additionally, the authorized, issued and outstanding shares of preferred stock and their related per share amount, other than the conversion price per share, were not adjusted as a result of the Reverse Stock Split.

Development-Stage Risks, Liquid

Development-Stage Risks, Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Development Activity Risks, Liquidity and Going Concern	(2) Development Activity Risks, Liquidity and Going Concern The Company has incurred operating losses since inception and has negative cash flows, working capital and equity, including accumulated deficit of $ 181,654 , as of September 30, 2022. The Company has raised funds from debt and equity transactions and will be required to raise additional funds to continue to operate as a standalone entity. In order to fund development activities, clinical and pre-clinical testing, small scale commercialization of ANJESO and, if approved, commercialization of the Company’s other product candidates, the Company will require significant additional funding. The Company could delay clinical trial activity or reduce funding of specific programs in order to reduce cash needs. Insufficient funds may cause the Company to delay, reduce the scope of or eliminate one or more of its development, commercialization, or expansion activities. The Company may raise such funds, if available, through debt financings, bank or other loans, through strategic research and development, licensing (including out-licensing) and/or marketing arrangements or through public or private sales of equity or debt securities from time to time. Financing may not be available on acceptable terms, or at all, and failure to raise capital when needed could materially adversely impact the Company’s growth plans and its financial condition or results of operations and ability to continue as a going concern. Additional debt or equity financing, if available, may be dilutive to holders of the Company’s common stock and may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate its business. The Company follows the provisions of Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”), Topic 205-40, “Presentation of Financial Statements — Going Concern”, or ASC 205-40, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. Based on the Company’s available cash and cash equivalents as of September 30, 2022 , management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued. The Company expects to seek additional funding to sustain its future operations and while the Company has successfully raised capital in the past, the ability to raise capital in future periods is not assured. The Company is not expected to be able to maintain its minimum liquidity covenant over the next twelve months without additional inflows of funds or capital financing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Principles	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	Summary of Significant Accounting Principles (a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), for interim financial information and with the instructions of Form 10-Q and Article 10 of Regulation S-X and, therefore, do not include all of the information and notes required by U.S. GAAP for complete annual financial statements. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2021 included in the Company’s Form 10-K. (b) Use of Estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. (c) Cash and Cash Equivalents Cash and cash equivalents represents cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired to be cash equivalents. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value because of the changes in interest rates. (d) Investments Investments generally consist of government money market funds and commercial paper with maturity of greater than three months when acquired and does not meet the definition of a cash or cash equivalents. The Company has historically classified its entire investment portfolio as available-for-sale debt securities and is carried at fair value with unrealized gains and losses included in comprehensive loss in the consolidated statement of operations and realized gains and losses included in other income/expense, if applicable. The Company uses benchmark inputs and industry standard analytical models to derive the fair value of its commercial paper. (e) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to seven years for furniture and office equipment; six to ten years for manufacturing equipment; and the shorter of the remaining lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. (f) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a one-step method for determining impairment. The one-step quantitative test calculates the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has one reporting unit. The Company performs its annual goodwill impairment test as of November 30 th , or whenever an event or change in circumstances occurs that would require reassessment of the recoverability of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance of its reporting unit, anticipated changes in industry and market conditions, including recent tax reform, intellectual property protection, and competitive environments. The Company performed an impairment test as of September 30, 2022 after identifying indicators of impairment. There was no impairment to goodwill based on the analysis. The Company’s intangible asset is classified as an asset resulting from R&D activities. The Company determined the useful life of its asset resulting from R&D activities to be approximately 10 years , which is based on the remaining patent life at the time of FDA approval and is being amortized on a straight-line basis. The Company is required to review the carrying value of assets resulting from R&D activities for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of intangible assets is measured by comparing the carrying value of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured by the amount the carrying value of the assets exceeds the fair value of the assets. The Company performed an impairment test as of September 30, 2022 after identifying indicators of impairment, including a decline in share price, the termination of the dedicated commercial team and sustained impacts of COVID-19 on the market. Based on the quantitative analysis an impairment loss of $ 17,746 was recorded as of September 30, 2022 to reduce the carrying value of the intangible asset. (g) Revenue Recognition The Company sells ANJESO in the U.S. through a single third-party logistics provider (“3PL”), which takes title to and control of the goods, and is considered the customer. The Company recognizes revenue from ANJESO product sales at the point the title to the product is transferred to the customer and the customer obtains control of the product. The transaction price that is recognized as revenue for products includes an estimate of variable consideration for reserves, which result from discounts, returns, chargebacks, rebates, and other allowances that are offered within contracts between the Company and end-user customers, wholesalers, group purchasing organizations and other indirect customers. The Company’s payment terms are generally between thirty to ninety days . The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available. These reserves reflect the Company’s best estimate of the amount of consideration to which the Company is entitled based on the terms of the contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that is considered probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. (h) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balance as of September 30, 2022 and December 31, 2021 is compromised solely from transactions with the Company’s 3PL. (i) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist of internal costs and funds paid to third parties for the provision of services for pre-commercialization and manufacturing scale-up activities, drug development, pre-clinical activities, clinical trials, statistical analysis, report writing and regulatory filing fees and compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development project. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining product technology licenses are charged to research and development expense as acquired in-process research and development (“IPR&D”) if the technology licensed has not reached technological feasibility and has no alternative future use. (j) Stock-Based Awards Share-based compensation included in the consolidated financial statements is based upon the Baudax Bio, Inc. 2019 Equity Incentive Plan (the “2019 Plan”). The plan includes grants of stock options, time-based vesting restricted stock units (“RSUs”) and performance-based RSUs. The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses an average of its peer group’s volatility in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company has never declared or paid cash dividends and has no plans to do so in the foreseeable future, therefore the dividend yield is zero. (k) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Because of the Company’s history of losses as a standalone entity, a full valuation allowance is recorded against deferred tax assets in all periods presented. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year. (l) Net Loss Per Common Share Net loss per common share is computed using the two-class method required due to the participating nature of the Series A Preferred Stock (as defined and discussed in Note 13(b)). Except with respect to voting and conversion, the rights of the holders of the Company’s common stock and the Company’s Series A Preferred Stock are identical. Each class of shares has the same rights to dividends. Although the Preferred Stock are participating securities, such securities do not participate in net losses and therefore do not impact the Company’s net loss per share calculation as of September 30, 2022. Basic net loss per common share is determined by dividing net loss attributable to common shareholders by the weighted average common shares outstanding during the period. Diluted net loss per common share is determined using the weighted average common shares outstanding during the period plus the weighted average number of shares of common shares that would be issued assuming exercise or conversion of all potentially dilutive instruments. Outstanding warrants, common stock options and unvested restricted stock units are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive. For purposes of calculating basic and diluted loss per common share, the denominator includes the weighted average common shares outstanding, the weighted average common stock equivalents for warrants priced at par value, or $ 0.01 , as the underlying common shares will be issued for little cash consideration and the conditions for the issuance of the underlying common shares are met when such warrants are issued, and, with regard to diluted loss per common share, the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. The following table sets forth the computation of basic and diluted loss per share: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Basic and Diluted Loss Per Share Net loss $ ( 29,205 ) $ ( 16,962 ) $ ( 49,545 ) $ ( 49,203 ) Weighted average common shares 11,836,122 2,411,433 7,685,398 2,112,247 Net loss per share of common stock, $ ( 2.47 ) $ ( 7.03 ) $ ( 6.45 ) $ ( 23.29 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Options and restricted stock units outstanding 606,652 151,955 606,652 151,955 Warrants 31,298,007 1,095,984 31,298,007 1,095,984 Amounts in the table above reflect the common stock equivalents of the noted instruments. (m) Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ,” or ASU 2020-06. ASU 2020-06 simplifies accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company adopted this guidance as of January 1, 2022, using the full retrospective method of adoption. The adoption eliminated the presentation of the beneficial conversion feature on the consolidated statement of operations and had no other material impact to the Company. In May 2021, the FASB issued ASU No. 2021-04, “ Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ,” or ASU 2021-04. ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options, such as warrants, that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years and early adoption is permitted. The Company adopted this guidance as of January 1, 2022, using the prospective method of adoption. This adoption did not have a material impact to the Company or its disclosures. In November 2021, the FASB issued ASU No. 2021-10, “ Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance ,” or ASU 2021-10. ASU 2021-10 requires entities to provide disclosures on government assistance transactions for annual reporting periods. The disclosures include information around the nature of the transaction, the related accounting policies used to account for the transaction, the effect of the transaction on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. ASU 2021-10 is effective for fiscal years beginning after December 15, 2021 and early adoption is permitted. The Company adopted this guidance as of January 1, 2022, using the prospective method of adoption. This adoption did not have a material impact to the Company or its disclosures. Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ,” or ASU 2016-13. ASU 2016-13 requires companies to measure credit losses utilizing a methodology that reflects expected credit losses and requires consideration of a range of reasonable information to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including those interim periods within those fiscal years. The Company is currently assessing the impact of adopting this standard, but based on a preliminary assessment, does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(4) Fair Value of Financial Instruments The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, warrants, and contingent consideration. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices Significant Significant At September 30, 2022: Assets: Cash equivalents (See Note 5) Money market mutual funds $ 2,225 $ — $ — Total cash equivalents $ 2,225 $ — $ — Liabilities: Warrants (See Note 13(c)) $ — $ — $ — Contingent consideration (See Note 12(b)) — — 21,408 $ — $ — $ 21,408 At December 31, 2021: Assets: Cash equivalents (See Note 5) Money market mutual funds $ 10,110 $ — $ — Total cash equivalents $ 10,110 $ — $ — Liabilities: Warrants (See Note 13(c)) $ — $ — $ 7 Contingent consideration (See Note 12(b)) — — 23,862 $ — $ — $ 23,869 The reconciliation of the warrant liability and contingent consideration measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Balance at December 31, 2020 $ 65 $ 65,043 Payment of contingent consideration — ( 7,869 ) Remeasurement ( 58 ) ( 33,312 ) Balance at December 31, 2021 $ 7 $ 23,862 Payment of contingent consideration — ( 1,200 ) Remeasurement ( 7 ) ( 1,254 ) Total at September 30, 2022 $ — $ 21,408 Current portion as of September 30, 2022 $ — $ 8,436 Long-term portion as of September 30, 2022 — 12,972 See Note 13(c) for the significant assumptions and inputs used to determine the fair value of liability classified warrants. Based on the amended terms of the Alkermes agreement (see Note 12(b)), the remaining contingent consideration payments include the second components, which became payable upon regulatory approval, and includes remaining payments of $ 45,000 payable in seven equal annual payments of approximately $ 6,400 of which the first payment was made in February 2021, the first anniversary of such approval. The third component consists of three potential payments, based on the achievement of specified annual revenue targets, which currently do not have a fair value assigned to its achievement. The fourth component consists of a royalty payment between 10 % and 12 % (subject to a 30 % reduction when no longer covered by patent) for a defined term on future injectable meloxicam net sales. The fair value of the remaining second consideration component is estimated by applying a risk-adjusted discount rate to the scheduled remaining payments. The fair value of the third contingent consideration component is estimated using the Monte Carlo simulation method and applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections based upon the expected revenue target attainment dates. The fair value of the fourth contingent consideration component is estimated by applying a risk-adjusted discount rate to the potential payments resulting from probability-weighted revenue projections and the defined royalty percentage. As of September 30, 2022 , the fair value calculations used a discount rate of 35.00 %. The fair value of the contingent consideration liability is measured using inputs and assumptions as of the date of the financial statements. The current portion of the contingent consideration represents the estimated probability-adjusted fair value that is expected to become payable within one year as of September 30, 2022. Events and circumstances impacting the fair value of the liability that occur after the balance sheet date, but before the date that the financial statements are available to be issued, are adjusted in the period during which such events and circumstances occur. These fair values are based on significant inputs not observable in the market, which are referred to in the guidance as Level 3 inputs. The contingent consideration components are classified as liabilities and are subject to the recognition of subsequent changes in fair value through the results of operations. The Company follows the disclosure provisions of FASB ASC Topic 825, “ Financial Instruments ”, for disclosure purposes for financial assets and financial liabilities that are not measured at fair value. As of September 30, 2022, the financial assets and liabilities recorded on the Consolidated Balance Sheets that are not measured at fair value on a recurring basis include accounts receivable, accounts payable and accrued expenses, which approximate fair value due to the short-term nature of these instruments. The fair value of debt, where a quoted market price is not available, is evaluated based on, among other factors, interest rates currently available to the Company for debt with similar terms, remaining payments and considerations of the Company’s creditworthiness. The Company determined that the recorded book value of debt approximated fair value at September 30, 2022 due to the fact that the debt arrangements reflect market terms from recent transactions.

Cash Equivalents

Cash Equivalents	9 Months Ended
	Sep. 30, 2022
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Cash Equivalents	(5) Cash Equivalents The following is a summary of cash equivalents: September 30, 2022 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 2,225 $ — $ — $ 2,225 Total cash equivalents $ 2,225 $ — $ — $ 2,225 December 31, 2021 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 10,110 $ — $ — $ 10,110 Total cash equivalents $ 10,110 $ — $ — $ 10,110 As of September 30, 2022 and December 31, 2021 , the Company’s cash equivalents had maturities of one month .

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	(6) Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. The Company expensed costs related to inventory within the Research and development line in the Consolidated Statements of Operations until it received approval from the FDA to market a product, at which time the Company commenced capitalization of costs relating to that product. Adjustments to inventory are determined at the raw material, sub-assemblies and finished goods levels to reflect obsolescence or impaired balances. Inventory consists of the following: September 30, 2022 December 31, 2021 Raw materials $ 26 $ 53 Sub-assemblies 4,015 4,656 Finished goods 1,630 645 5,671 5,354 Provision for inventory obsolescence ( 1,194 ) ( 352 ) Inventory $ 4,477 $ 5,002

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	(7) Property, Plant and Equipment Property, plant and equipment consists of the following: September 30, 2022 December 31, 2021 Building and improvements $ 166 $ 196 Furniture, office and computer equipment 841 952 Manufacturing and laboratory equipment 717 717 Construction in progress 980 4,622 2,704 6,487 Less: accumulated depreciation 1,465 1,472 Property and equipment, net $ 1,239 $ 5,015 Depreciation expense for the three and nine months ended September 30, 2022 was $ 39 and $ 125 , respectively. Depreciation expense for the three and nine months ended September 30, 2021 was $ 46 and $ 195 , respectively. The Company recorded an i mpairment loss on property and equipment of $ 3,662 during the three and nine months ended September 30, 2022 , which represents the non-cash impairment charge recorded for assets that were previously capitalized in connection with the construction of a second manufacturing suite at the Alkermes manufacturing facility. The suite is no longer planned to be used for production. There were no such impairment charges reported during the three and nine months ended September 30, 2021 .

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	(8) Leases The Company is a party to various operating leases in Malvern, Pennsylvania, and Dublin, Ireland for office space and office equipment. Right-of-use assets are recorded on the Consolidated Balance Sheet in other long-term assets. Operating lease liabilities are recorded on the Consolidated Balance Sheet in accrued expenses and other current liabilities and other long-term liabilities, based on the timing of expected cash payments. The Company determines if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Lease terms vary based on the nature of operations. The current leased facility recorded on the Consolidated Balance Sheet is classified as an operating lease with a remaining lease term of 5 years . Most leases contain specific renewal options where notice to renew must be provided in advance of lease expiration or automatic renewals where no advance notice is required. Periods covered by an option to extend the lease were included in the non-cancellable lease term when exercise of the option was determined to be reasonably certain. Costs determined to be variable and not based on an index or rate were not included in the measurement of operating lease liabilities. As most leases do not provide an implicit rate, the Company’s effective interest rate was used to discount its lease liabilities. The Company’s leases with an initial term of twelve months or less that do not have a purchase option or extension that is reasonably certain to be exercised are not included in the right of use asset or lease liability on the Consolidated Balance Sheets. Lease expense is recognized on a straight-line basis over the lease term. As of September 30, 2022, undiscounted future lease payments for non-cancellable operating leases are as follows: Lease payments Remainder of 2022 $ 111 2023 270 2024 278 2025 278 2026 287 2027 295 Total lease payments 1,519 Less imputed interest ( 678 ) Total operating lease liability $ 841 As of September 30, 2022, the weighted average remaining lease term was 5 years and the weighted average discount rate was 23 % . The components of the Company’s lease cost were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost $ 70 $ 79 $ 215 $ 255 Short-term lease cost 33 52 106 130 Total lease cost $ 103 $ 131 $ 321 $ 385 Cash paid for amounts included in the measurement of lease liabilities, which is included in operating cash flows, was $ 254 and $ 258 for the nine months ended September 30, 2022 and 2021 , respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(9) Intangible Assets The following represents the balances of the intangible assets: September 30, 2022 December 31, 2021 Asset resulting from R&D activities $ 26,400 $ 26,400 Accumulated Amortization ( 6,654 ) ( 4,722 ) Impairment loss ( 17,746 ) — Intangible assets, net $ 2,000 $ 21,678 Amortization expense for the three and nine months ended September 30, 2022 was $ 644 and $ 1,932 , respectively. Amortization expense for the three and nine months ended September 30, 2021 was $ 644 and $ 1,932 , respectively. During the nine months ended September 30, 2022 , the Company recorded an impairment loss of $ 17,746 to reduce the carrying value of the intangible asset as a result of current estimates of its expected net fair value. As of September 30, 2022, future amortization expense is as follows: Amortization Remainder of 2022 $ 65 2023 261 2024 261 2025 261 2026 261 2027 and thereafter 891 Total $ 2,000

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	(10) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: September 30, December 31, 2022 2021 Payroll and related costs $ 2,143 $ 3,516 Professional and consulting fees 667 1,071 Other research and development costs 61 157 Interest payable 100 116 Other 348 680 $ 3,319 $ 5,540 In November 2020, the Company implemented a reduction in force impacting approximately 40 employees and resulted in a charge of $ 1,753 , primarily related to severance, of which $ 25 remains accrued and unpaid as of September 30, 2022. In March 2022, the Company implemented a reduction in force impacting approximately 66 employees and resulted in a charge of $ 4,148 , primarily related to severance, of which $ 1,267 remains accrued and unpaid as of September 30, 2022 . Further, in September 2022, the Company eliminated the remaining dedicated commercial team of approximately 7 employees, which resulted in a third quarter charge of $ 241 , primarily related to severance, of which $ 193 remains accrued and unpaid as of September 30, 2022 .

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	(11) Debt The following table summarizes the components of the carrying value of debt: September 30, December 31, 2022 2021 Credit Agreement $ 10,000 $ 10,000 Payment of principal ( 1,112 ) — Unamortized deferred issuance costs ( 969 ) ( 1,583 ) Exit fee accretion 167 114 Total debt $ 8,086 $ 8,531 Current portion $ 5,911 $ 2,222 Long-term portion, net 2,175 6,309 (a) Credit Agreement On May 29, 2020 (the “Credit Agreement Closing Date”), the Company entered into a $ 50,000 Credit Agreement (the “Credit Agreement”) by and among the Company, Wilmington Trust, National Association, in its capacity as the agent (“Agent”), and MAM Eagle Lender, LLC, as the lender (together with any other lenders under the Credit Agreement from time to time, collectively, the “Lenders”). The Credit Agreement provides for a term loan in the original principal amount of $ 10,000 (the “Tranche One Loans”) funded on the Credit Agreement Closing Date. Pursuant to the terms of the Credit Agreement, there are four additional tranches of term loans, in an aggregate original principal amount of $ 40,000 (the “Tranche Two Loans”, “Tranche Three Loans”, “Tranche Four Loans” and the “Tranche Five Loans”, and collectively with the Tranche One Loans, the “Term Loans” and each a “Term Loan”). As of September 30, 2022 , no funds have been drawn from the additional tranches. The Tranche Two Loans in an amount not to exceed $ 5,000 may be drawn upon on or before August 29, 2021 provided that the Company generates at least $ 5,000 in net revenue in the three consecutive calendar months immediately preceding the date such Tranche Two Loans are funded. The Tranche Two Loans may also be drawn on a subsequent date with the satisfaction of the conditions for the Tranche Three Loans, Tranche Four Loans, or Tranche Five Loans, as applicable, provided that the Tranche Two Loans may not be drawn more than once. The Tranche Three Loans in an amount not to exceed $ 5,000 may be drawn upon on or before November 29, 2021 provided that the Company generates at least $ 10,000 in net revenue in the three consecutive calendar months immediately preceding such date such Tranche Three Loans are funded. The Tranche Three Loans may also be drawn on a subsequent date with the satisfaction of the conditions for the Tranche Four Loans or Tranche Five Loans, as applicable, provided that the Tranche Three Loans may not be drawn more than once. The Tranche Four Loans in an amount not to exceed $ 10,000 may be drawn upon, subject to the consent of the Lenders, on or before August 29, 2022 provided that the Company generates at least $ 20,000 in net revenue in the three consecutive calendar months immediately preceding the date such Tranche Four Loans are funded. The Tranche Four Loans may also be drawn on a subsequent date with the satisfaction of the conditions for the Tranche Five Loans provided that the Tranche Four Loans may not be drawn more than once. The Tranche Five Loans in an amount not to exceed $ 20,000 may be drawn upon, subject to the consent of the Lenders, on or before March 1, 2023 provided that the Company generates at least $ 100,000 in net revenue in the twelve consecutive calendar months immediately preceding the date such Tranche Five Loans are funded. The Company does not expect to draw additional loan tranches from the Credit Agreement as of September 30, 2022. The Term Loans will bear interest at a per annum rate equal to 13.5 %, with monthly , interest-only payments until the date that is three years prior to the Maturity Date (as defined below) (the “Amortization Date”). The maturity date of the Credit Agreement is May 29, 2025 , but may be extended to May 29, 2026 provided that the EBITDA (as defined in the Credit Agreement) for the consecutive twelve-month period ending on or immediately prior to May 29, 2022 is greater than $ 10,000 (such date, “Maturity Date”), which the Company did not achieve. Beginning on the Amortization Date, the Company will be obligated to pay amortization payments (in addition to the interest stated above) on such date and each month thereafter in equal month installments of principal based on an amortization schedule of thirty-six months . Any unpaid principal amount of the Term Loans is due and payable on the Maturity Date. Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans, with the proceeds of asset sales, extraordinary receipts, debt issuances and specified other events. The Company may make voluntary prepayments in whole or in part, subject to a prepayment premium equal to (i) with respect to any prepayment paid on or prior to the third anniversary of the Tranche One Loan (or, in the case of each of the Tranche Two Loans, Tranche Three Loans, Tranche Four Loans or Tranche Five Loans, the third anniversary of the date each such loan is funded), the remaining scheduled payments of interest that would have accrued on the Term Loans being prepaid, repaid or accelerated, but that remained unpaid, in no event to be less than 5.0 % of the principal amount of the Term Loan being prepaid, and (ii) with respect to any prepayment paid after the third but prior to the fourth anniversary of the Tranche One Loan (or, in the case of each of the Tranche Two Loans, Tranche Three Loans, Tranche Four Loans or Tranche Five Loans, the fourth anniversary of the date each such loan is funded), 3.0 % of the principal amount of the Term Loan being prepaid. In addition, an exit fee will be due and payable upon prepayment or repayment of the Term Loans (including, without limitation, on the Maturity Date) equal to the lesser of 2.5 % of the sum of the aggregate principal amount of the Term Loans advanced or approved to be advanced by the Lenders and $ 700 ; provided that such exit fee will be equal to $ 700 if fee is paid in conjunction with a change of control that occurs in connection with the payoff or within 6 months thereof. As of September 30, 2022 , the Company will have to pay a 2.5 % exit fee, which is $ 250 at the current outstanding loan balance and is being accreted to the carrying amount of the debt using the effective interest method over the term of the loan. The Credit Agreement contains certain usual and customary affirmative and negative covenants, as well as financial covenants including a minimum liquidity requirement of $ 5,000 at all times (the “Minimum Liquidity Covenant”) and minimum EBITDA levels that the Company may need to satisfy on a quarterly basis beginning in September 2021, subject to borrowing levels. As of September 30, 2022, the Company was in compliance with the Minimum Liquidity Covenant as the minimum EBITDA criteria is not applicable until additional tranches are drawn. As of September 30, 2022, borrowings under the Credit Agreement are classified based on their schedule maturities. In connection with the Credit Agreement, the Company issued a warrant to MAM Eagle Lender, LLC to purchase 15,060 shares of the Company’s common stock, at an exercise price equal to $ 160.65 per share. See Note 13(c) for additional information. The warrant is exercisable through May 29, 2027 . The Company recorded debt issuance costs for the Credit Agreement of $ 1,496 plus the fair value of warrants of $ 1,423 , which are being amortized using the effective interest method over the term of Credit Agreement. Debt issuance cost amortization is included in interest expense within the Consolidated Statements of Operations. As of September 30, 2022, the effective interest rate was 22.67 % , which takes into consideration the non-cash amortization of the debt issuance costs and accretion of the exit fee. The Company recorded debt issuance cost amortization related to the Credit Agreement of $ 193 and $ 614 for the three and nine months ended September 30, 2022, respectively, and $ 211 and $ 633 for the three and nine months ended September 30, 2021, respectively. On August 1, 2022, the Company entered into Amendment No. 1 and Waiver to Credit Agreement, or the Amendment, with MAM Eagle Lender. Pursuant to the terms of the Amendment, the lenders waived any default under the credit agreement (including the imposition of a default interest rate with respect to the default) resulting from our failure to comply with the Minimum Liquidity Covenant. In addition, the Amendment, among other items, (i) provides that 30 % of any cash proceeds received by the Company from certain potential strategic licensing transactions shall be used to prepay amounts outstanding under the credit agreement; and (ii) decreases the amount of cash the Company is required to maintain pursuant to the Minimum Liquidity Covenant to $ 3,000 for a period beginning on August 1, 2022, and ending on August 31, 2022, at which point the amount required pursuant to the Minimum Liquidity Covenant shall increase to $ 5,000 . On October 24, 2022, the Company entered into Amendment No. 2 and Waiver to Credit Agreement, or the Amendment, with MAM Eagle Lender. Pursuant to the terms of the Amendment, the Credit Agreement is amended such that the Company must repay the principal thereunder (i) on the first business day of each month until the Interest Payment Date on December 1, 2022, in equal monthly installments of principal based on an amortization schedule of 36 months, (ii) an additional payment of principal in the amount of $ 300 prior to December 31, 2022 and (iii) commencing on the Interest Payment Date on January 2, 2023 and on each Interest Payment Date thereafter until the obligations have been repaid in full, the principal amount of $ 500 . In addition, the Amendment decreases the minimum cash covenant the Company is required to maintain under the Credit Agreement to (i) $ 3,000 for the period beginning on October 1, 2022, and ending on November 30, 2022, (ii) $ 4,500 for the period beginning on December 1, 2022, and ending on February 28, 2023, and (iii) $ 4,000 from and after March 1, 2023. Further, the Company has agreed that prior to December 31, 2022, it shall not, without the prior written consent of the Lenders, make or permit any payment under its agreements with Alkermes. In consideration for the Amendment, the Company agreed to pay the Agent an amendment fee of $ 5 and the Lender an amendment fee of $ 200 . As a result of the liquidity conditions discussed in Note 2, the Company is not expected to be able to comply with the Minimum Liquidity Covenant, as amended, over the next twelve months without additional capital financing. If the Company is unable to maintain its Minimum Liquidity Covenant, it is reasonably possible that the Lenders could demand repayment of the borrowings under the Credit Agreement during the next twelve months.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies (a) Licenses and Supply Agreements The Company is party to an exclusive license with Orion Corporation, a company incorporated under the laws of Finland (“Orion”) for the development and commercialization of Dexmedetomidine for use in the treatment of pain in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, but specifically excluding delivery vehicles for administration by injection or infusion, worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory. The Company is required to pay Orion lump sum payments of up to € 20,500 ($ 20,084 as of September 30, 2022 ) on the achievement of certain developmental and commercial milestones, as well as a royalty on net sales during the term, which varies from 10 % to 20 % depending on annual sales levels. Through September 30, 2022 , no such milestones have been achieved. The Company is also party to an exclusive license agreement with Orion for the development and commercialization of Fadolmidine for use as a human therapeutic, in any dosage form in the Territory. The Company is required to pay Orion lump sum payments of up to € 12,200 ($ 11,954 as of September 30, 2022 ) on achievement of certain developmental and commercial milestones, as well as a royalty on net sales during the term, which varies from 10 % to 15 % depending on annual sales levels. Through September 30, 2022 , no such milestones have been achieved. In June 2017, the Company acquired the exclusive global rights to two novel neuromuscular blocking agents (“NMBs”) and a proprietary reversal agent from Cornell University (“Cornell”). The NMBs and reversal agent are referred to herein as the NMB Related Compounds. The NMB Related Compounds include one novel intermediate-acting NMB that has initiated Phase I clinical trials and two other agents, a novel short-acting NMB, and a rapid-acting reversal agent specific to these NMBs. The Company is obligated to make: (i) an annual license maintenance fee payment to Cornell in the remaining range of $ 70 to $ 125 until the first commercial sale of the NMB Related Compounds; and (ii) milestone payments to Cornell upon the achievement of certain milestones, up to a maximum, for each NMB Related Compound, of $ 5,000 for U.S. regulatory approval and commercialization milestones and $ 3,000 for European regulatory approval and commercialization milestones. The Company is obligated to pay Cornell royalties on net sales of the NMB Related Compound at a rate ranging from low to mid-single digits, depending on the applicable NMB Related Compounds and whether there is a valid patent claim in the applicable country, subject to an annual minimum royalty amount. Further, the Company reimburses Cornell for its ongoing patent costs related to prosecution and maintenance of the patents related to the Cornell patents for the NMB Related Compounds. Through September 30, 2022 , no such milestones have been achieved. The Company is party to a Development, Manufacturing and Supply Agreement (“Supply Agreement”), with Alkermes plc (“Alkermes”) (through a subsidiary of Alkermes), pursuant to which Alkermes will (i) provide clinical and commercial bulk supplies of ANJESO formulation and (ii) provide development services with respect to the Chemistry, Manufacturing and Controls section of a New Drug Application (“NDA”) for ANJESO. Pursuant to the Supply Agreement, Alkermes will supply the Company with such quantities of bulk ANJESO formulation as shall be reasonably required for the completion of clinical trials of ANJESO. During the term of the Supply Agreement, the Company will purchase its clinical and commercial supplies of bulk ANJESO formulation exclusively from Alkermes, subject to certain exceptions, for a period of time. The Company is party to a Master Manufacturing Services Agreement and Product Agreement with Patheon UK Limited, a company incorporated under the laws of England (“Patheon”), collectively the Patheon Agreements, pursuant to which Patheon provides sterile fill-finish of injectable meloxicam drug product at its Monza, Italy manufacturing site. The Company has agreed to purchase a certain percentage of its annual requirements of finished injectable meloxicam from Patheon during the term of the Patheon Agreements. (b) Contingent Consideration for the Alkermes Transaction On April 10, 2015, Societal CDMO completed the acquisition of a manufacturing facility in Gainesville, Georgia and the licensing and commercialization rights to injectable meloxicam (the “Alkermes Transaction”). Pursuant to the purchase and sale agreement and subsequent amendment with Alkermes, as amended, governing the Alkermes Transaction, the Company agreed to pay to Alkermes up to an additional $ 140,000 in milestone payments including $ 60,000 upon regulatory approval payable over a seven-year period, as well as net sales milestones related to injectable meloxicam and royalties on future product sales of injectable meloxicam. Based on the amended terms of the Alkermes agreement, the contingent consideration consists of four separate components. The first component was (i) a $ 5,000 payment made in the first quarter of 2019 and (ii) a $ 5,000 payment made in the second quarter of 2019. The second components became payable upon regulatory approval in February 2020 and include (i) a $ 5,000 payment, which was paid in three installments during 2020 and 2021, and (ii) $ 45,000 payable in seven equal annual payments of approximately $ 6,400 beginning on the first anniversary of such approval, of which the first payment was made in the first quarter of 2021. The Company paid $ 1,200 of the second payment, which was due in the first quarter of 2022, and will make payments thereafter until the second payment is fully paid, as agreed between the Company and Alkermes. The third component consists of three potential payments, based on the achievement of specified annual revenue targets, which currently do not have a fair value assigned to its achievement. The fourth component consists of a royalty payment between 10 % and 12 % (subject to a 30 % reduction when no longer covered by patent) for a defined term on future injectable meloxicam net sales, which is paid quarterly. In October 2022, the Company entered into the Amendment with MAM Eagle lender and has agreed that prior to December 31, 2022, it shall not, without the prior written consent of the Lenders, make or permit any payment under its agreements with Alkermes. As of September 30, 2022, the Company has paid $ 22,629 in milestone payments to Alkermes. (c) Litigation The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company accrues for any legal costs as they are incurred. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations. In connection with the Separation, the Company accepted assignment by Societal CDMO of all of Societal CDMO’s obligations in connection with a securities class action lawsuit (the “Securities Litigation”) and agreed to indemnify Societal CDMO for all liabilities related to the Securities Litigation. On May 31, 2018, the Securities Litigation was filed against Societal CDMO and certain of Societal CDMO’s officers and directors in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:18-cv-02279-MMB) that purported to state a claim for alleged violations of Section 10(b) and 20(a) of the Exchange Act and Rule 10(b)(5) promulgated thereunder, based on statements made by Societal CDMO concerning the NDA for ANJESO. The complaint seeks unspecified damages, interest, attorneys’ fees, and other costs. On December 10, 2018, the lead plaintiff filed an amended complaint that asserted the same claims and sought the same relief but included new allegations and named additional officers as defendants. On February 8, 2019, Societal CDMO filed a motion to dismiss the amended complaint in its entirety, which the lead plaintiff opposed on April 9, 2019. On May 9, 2019, Societal CDMO filed its response and briefing was completed on the motion to dismiss. In response to questions from the Judge, the parties submitted supplemental briefs with regard to the motion to dismiss the amended complaint during the fall of 2019. On February 18, 2020, the motion to dismiss was granted without prejudice. On April 25, 2020, the plaintiff filed a second amended complaint. Societal CDMO filed a motion to dismiss the second amended complaint on June 18, 2020. The plaintiff filed an opposition to the motion to dismiss on August 17, 2020. On September 16, 2020, Societal CDMO filed a reply in support of the motion to dismiss. On March 1, 2021, Societal CDMO’s second motion to dismiss was denied. On June 21, 2021, the defendants filed an answer and affirmative defenses to the second amended complaint. Since then, the parties have been engaged in discovery, which concluded by March 15, 2022. On September 30, 2021, the plaintiff filed a motion for class certification and appointment of class representative. Societal CDMO filed an opposition to the plaintiff’s motion on November 30, 2021. On January 6, 2022, the plaintiff filed a reply in support of the motion for class certification. On March 24, 2022, the plaintiff informed the Court that the parties had reached an agreement-in-principle to settle the Securities Litigation and requested that the court stay all deadlines. On May 10, 2022, plaintiff filed an unopposed motion for preliminary approval of the class action settlement. The Court entered an order preliminarily approving the settlement and providing for notice on May 12, 2022. A hearing for final approval of the settlement was held on October 26, 2022, and the parties are awaiting a decision. (d) Purchase Commitments As of September 30, 2022, the Company had outstanding non-cancelable and cancelable purchase commitments in the aggregate amount of $ 3,419 primarily related to manufacturing and development activities and other goods and services. The timing of certain purchase commitments cannot be estimated as it is dependent on the outcome of other strategic evaluations and agreements. (e) Certain Compensation and Employment Agreements The Company entered into an employment agreement with one of its named executive officers in February 2020. As of September 30, 2022, this employment agreement provided for, among other things, annual base salary in an aggregate amount of not less than $ 927 , from that date through March 2023 .

Capital Structure

Capital Structure	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Capital Structure	(13) Capital Structure (a) Common Stock On November 21, 2019, the Company separated from Societal CDMO as a result of a special dividend distribution of all the outstanding shares of its common stock to Societal CDMO shareholders. On the distribution date, each Societal CDMO shareholder received one share of Baudax Bio’s common stock for every two and one-half shares of Societal CDMO common stock held of record at the close of business on November 15, 2019. Upon the Distribution, 268,473 shares of common stock were issued, of which 1,311 were distributed after December 31, 2019. The Company is authorized to issue 190,000,000 shares of common stock, with a par value of $ 0.01 per share. On February 13, 2020, the Company entered into a Sales Agreement (the “ATM Facility”) with JMP Securities LLC, as sales agent (the “Agent”), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, par value $ 0.01 per share, in an aggregate offering price of up to $ 25,000 through the Agent. On May 27, 2021, the Company voluntarily terminated the ATM Facility with the Agent. During the term of the ATM Facility, the Company sold an aggregate of 12,628 shares of common stock under the ATM Facility for net proceeds of $ 3,612 . The Agent was paid a sales commission of 3 % for such sales under the ATM Facility. The ATM Facility was terminable at will by the Company with no penalty. On March 26, 2020, the Company closed an underwritten public offering of 219,780 shares of its common stock, Series A Warrants to purchase 219,780 shares of common stock (the “March Series A Warrants”) and Series B Warrants to purchase 219,780 shares of common stock (the “March Series B Warrants”), at an exercise price of $ 160.65 per share for the March Series A Warrants and at an exercise price of $ 113.75 per share for the March Series B Warrants, for net proceeds to the Company of $ 23,085 , after deducting underwriting discounts and commissions and offering expenses. On November 24, 2020, the Company closed a registered direct offering of 81,429 shares of its common stock, warrants to purchase 289,331 shares of common stock (the “November Series A Warrants”) at an exercise price of $ 42.00 per share, pre-funded warrants to purchase 207,902 shares of common stock (the “November Series B Warrants”) at an exercise price of $ 0.35 per share, for net proceeds to the Company of $ 10,763 . As compensation to H.C. Wainwright & Co., LLC (the “Placement Agent”) as placement agent, the Company agreed to pay to the Placement Agent a cash fee of 6.0 % of the aggregate gross proceeds, plus a management fee equal to 1.0 % of the gross proceeds and reimbursement of certain expenses and legal fees. The Company also issued warrants to purchase 17,357 shares of common stock (the “November Placement Agent Warrants”) at an exercise price of $ 51.84375 per share. On December 18, 2020, the Company closed a registered direct offering of 121,428 shares of its common stock, warrants to purchase 294,298 shares of common stock (the “December Series A Warrants”) at an exercise price of $ 41.30 per share, pre-funded warrants to purchase 172,869 shares of common stock (the “December Series B Warrants”) at an exercise price of $ 0.35 per share, for net proceeds to the Company of $ 10,933 . As compensation to the Placement Agent, the Company agreed to pay to the Placement Agent a cash fee of 6.0 % of the aggregate gross proceeds, plus a management fee equal to 1.0 % of the gross proceeds and reimbursement of certain expenses and legal fees. The Company also issued warrants to purchase 17,654 shares of common stock (the “December Placement Agent Warrants”) at an exercise price of $ 50.96875 per share. On February 8, 2021, the Company closed a registered direct offering of 314,286 shares of common stock (the “February Offering”) at an offering price of $ 56.00 per share for net proceeds to the Company of $ 16,187 . As compensation to the Placement Agent, the Company agreed to pay the Placement Agent a cash fee of 6.0 % of the gross proceeds raised in the February Offering, plus a management fee equal to 1.0 % of the gross proceeds raised in the February Offering and reimbursement of certain expenses and legal fees. The Company also issued to designees of the Placement Agent warrants to purchase 18,854 shares of common stock (the “February Placement Agent Warrants”) at an exercise price of $ 70.00 per share. On May 31, 2021, the Company closed a registered direct offering of 400,815 shares of common stock (the “May Offering”) at an offering price of $ 29.75 per share and warrants to purchase 400,812 shares of common stock (the “May Warrants”) at an exercise price of $ 31.50 per share, for net proceeds to the Company of $ 10,861 . As compensation to the Placement Agent, the Company agreed to pay the Placement Agent a cash fee of 6.0 % of the gross proceeds raised in the May Offering, plus a management fee equal to 1.0 % of the gross proceeds raised in the May Offering and reimbursement of certain expenses and legal fees. The Company also issued to designees of the Placement Agent warrants to purchase 24,046 shares of common stock (the “May Placement Agent Warrants”) at an exercise price of $ 37.1875 per share. The May Warrants and May Placement Agent Warrants were exercisable on the six-month anniversary of the closing date of the May Offering. On December 28, 2021, the Company closed a registered direct offering (the “December 2021 Offering”) of 42,289.3 shares of the Company’s Series A Preferred Stock, par value $ 0.01 per share (the “Preferred Stock”), at a stated value of $ 100.00 per share and warrants to purchase 362,479 shares of common stock of the Company (the “December 2021 Warrants”) for net proceeds of $ 3,658 . The shares of Preferred Stock are convertible, on the date after the issuance thereof, into an aggregate of 483,306 shares of common stock at a conversion price of $ 8.75 per share, of which 34,000 shares of Preferred Stock were converted to common stock on December 29, 2021 and the remaining were converted in the first quarter of 2022. The Preferred Stock have no voting rights, other than the right to vote as a class on certain matters, and each share of Preferred Stock will have the right to cast 3,571 votes per share of Preferred Stock on an amendment to the Company’s Amended and Restated Articles of Incorporation , as amended, to effect a reverse stock split of the Company’s outstanding shares of common stock by a ratio to be determined by the Board of Directors of the Company, voting together with the common stock as a single class; and in accordance with Nasdaq Stock Market LLC Listing Rules, the votes cast by holders of the Preferred Stock must be counted by the Company in the same proportion as the aggregate shares of Common Stock voted on the proposal. The holders of Preferred Stock are entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of common stock. The Company recognized a beneficial conversion charge of $ 2,422 during the year ended December 31, 2021, which represents the in-the-money value of the conversion rate as of the date of issuance. As compensation to the Placement Agent, the Company agreed to pay the Placement Agent a cash fee of 7.0 % of the gross proceeds raised in the December 2021 Offering, plus a management fee equal to 1.0 % of the gross proceeds raised in the December 2021 Offering and reimbursement of certain expenses and legal fees. The Company also issued to designees of the Placement Agent warrants to purchase 28,996 shares of common stock (the “December 2021 Placement Agent Warrants”). The December 2021 Warrants and the December 2021 Placement Agent Warrants have an exercise price of $ 11.20 per share and were exercisable upon the six-month anniversary of their issuance. On March 1, 2022, the Company closed an underwritten public offering of 1,831,631 shares of its common stock, pre-funded warrants to purchase 1,677,141 shares of common stock at an exercise price of $ 0.01 per share and warrants to purchase 3,508,772 shares of common stock at an exercise price of $ 3.25 per share, as well as up to 526,315 additional shares of common stock and/or additional warrants to purchase up to 526,315 shares of common stock, which may be purchased pursuant to a 30-day option to purchase additional securities granted to H.C. Wainwright & Co., LLC (the “Underwriter”) by the Company. The public offering price for each share of common stock and accompanying warrant to purchase one share of common stock was $ 2.85 , and the public offering price for each pre-funded warrant and accompanying warrant was $ 2.84 . As compensation to the Underwriter, the Company agreed to pay to the Underwriter a cash fee of 7.0 % of the gross proceeds, plus a cash management fee equal to 1.0 % of the gross proceeds and reimbursement of certain expenses and legal fees. The Company also issued to designees of the Underwriter warrants to purchase 210,526 shares of common stock at an exercise price of $ 3.5625 per share. On February 28, 2022, the Underwriter partially exercised its option to purchase an additional 113,896 warrants. Net proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, was $ 8,791 . On May 17, 2022, the Company entered into a securities purchase agreement with institutional investors named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “May 2022 Offering”), 1,646,091 shares of the Company’s common stock, par value $ 0.01 per share, and, in a concurrent private placement, warrants exercisable for up to an aggregate of 1,646,091 shares of Common Stock at a combined offering price of $ 1.215 per share and associated warrant. The warrants have an exercise price of $ 1.09 per share. Each warrant is exercisable for one share of common stock and was exercisable immediately upon issuance. The warrants will have a term of five years from the issuance date. As compensation to H.C. Wainwright & Co., LLC as placement agent in connection with the offering, the Company agreed to pay to the placement agent a cash fee of 7.0 % of the aggregate gross proceeds raised in the offering, plus a management fee equal to 1.0 % of the gross proceeds raised in the offering and certain expenses. The Company also issued to designees of the placement agent warrants to purchase up to 6.0 % of the aggregate number of shares of common stock sold in the transactions, or warrants to purchase up to 98,765 shares of common stock. The placement agent warrants have substantially the same terms as the warrants, except that the placement agent warrants have an exercise price equal to 125% of the offering price per share (or $ 1.5188 per share). The placement agent warrants will expire on May 17, 2027 . Net proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, was $ 1,720 . On September 1, 2022, the Company closed a best efforts public offering of: (i) 7,554,886 shares of its common stock, par value $ 0.01 per share and accompanying Series A-1 warrants (“Series A-1 warrants”) to purchase 7,554,886 shares of Common stock and Series A-2 warrants (“Series A-2 warrants”, and together with the Series A-1 warrants, “Series A warrants”) to purchase 7,554,886 shares of Common Stock, at a combined public offering price of $ 0.525 per share and Series A warrants and (ii) Series B pre-funded warrants (“Series B pre-funded warrants”) to purchase 4,264,286 shares of Common Stock and accompanying Series A-1 warrants to purchase 4,264,286 shares of Common Stock and Series A-2 warrants to purchase 4,264,286 shares of Common stock at a combined public offering price of $ 0.515 per Series B pre-funded warrant and Series A warrants, which is equal to the public offering price per share of Common Stock and accompanying Series A warrants less the $ 0.01 per share exercise price of each such Series B pre-funded warrant. The Series A warrants have an exercise price of $ 0.525 per share of Common Stock. The Series A-1 warrants are exercisable upon issuance and will expire five years from the date of issuance. The Series A-2 warrants are exercisable upon issuance and will expire thirteen months from the date of issuance. The exercise price of the Series A warrants is subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in the Series A warrants. Subject to certain ownership limitations, the Series B pre-funded warrants are immediately exercisable and were exercised at a nominal consideration of $ 0.01 per share of Common Stock upon the closing of the transaction. As compensation to H.C. Wainwright & Co., LLC, as the exclusive placement agent in connection with the Offering, the Company paid a cash fee of 7.0 % of the aggregate gross proceeds raised in the offering, plus a management fee equal to 1.0 % of the gross proceeds raised in the offering, and reimbursement of certain expenses and legal fees. The Company also issued to designees of the placement agent warrants to purchase up to 709,150 shares of common stock. The placement agent warrants have substantially the same terms as the Series A warrants, except that the placement agent warrants have an exercise price equal to $ 0.65625 per share and expire on August 29, 2027 . Net proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, was $ 5,065 . On November 3, 2022, shareholders approved an amendment to the Company's Amended and Restated Articles of Incorporation, as amended, which authorized the Board of Directors to effect a reverse stock split of the Company's common stock by a ratio of any whole number between 1-for-5 and 1-for-40. (b) Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $ 0.01 per share. On September 19, 2022, the board of directors of the Company declared a dividend of one one-thousandth (1/1,000th) of a share of Series B Preferred Stock, par value $ 0.01 per share (“Series B Preferred Stock”) , for each outstanding share of the Company’s common stock, par value $ 0.01 per share to shareholders of record on September 29, 2022 (the “Record Date”). The shares of Series B Preferred Stock were distributed to such recipients on October 3, 2022. Each share of Series B Preferred Stock entitles the holder thereof to 1,000,000 votes per share. The outstanding shares of Se ries B Preferred Stock vote together with the outstanding shares of Common Stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to the Company’s Amended and Restated Articles of Incorporation, as amended, to reclassify the outstanding shares of common stock into a smaller number of shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of shareholders called for the purpose of voting on the Reverse Stock Split. The Series B Preferred Stock will not be entitled to vote on any other matter, except to the extent required under the Pennsylvania Business Corporation Law. As of September 30, 2022 , 20,003.745 shares of Series B Preferred Stock were declared as a stock dividend and issued on October 3, 2022. On November 3, 2022, all of our outstanding shares of Series B Preferred Stock were redeemed for nominal consideration pursuant to the terms of the Series B Preferred Stock. All issued and outstanding shares of preferred stock contained in the financial statements have been retroactively adjusted to reflect this dividend for all period presented as if the distribution date of the shares of preferred stock occurred within those periods. See Note 13(a) for additional information regarding the December 2021 Offering. (c) Warrants On May 29, 2020, in connection with the Credit Agreement, the Company issued a warrant to MAM Eagle Lender, LLC to purchase 15,060 shares of common stock, at an exercise price equal to $ 160.65 per share (see Note 11(b)). On October 19, 2020, the Company entered into Warrant Exchange Agreements (each, an “Exchange Agreement”) with certain holders (each, a “Holder”) of the Company’s outstanding March Series A Warrants and March Series B Warrants. Pursuant to the Exchange Agreements, the Holders, at their election, agreed to a cashless exchange of either all of their March Series A Warrants or March Series B Warrants, in each case for 0.0057 shares of the Company’s common stock per warrant (rounded up to the nearest whole share) (the “Exchange”). The Company issued 33,908 shares of its common stock to the participating Holders as a result of the Exchange. As a result of the Exchange, pursuant to certain price adjustment provisions in the warrants, the exercise price of each of the March Series A Warrants or March Series B Warrants (including warrants held by holders not participating in the Exchange) that were not exchanged were adjusted to par value, or $ 0.35 , for each share of common stock underlying such warrant. Pursuant to the Exchange Agreements, any outstanding warrant held by a Holder participating in the Exchange (i) was amended to remove certain anti-dilution and variable pricing protections and (ii) in the case of March Series A Warrants not exchanged by a participating Holder, was amended to adjust the expiration date of such March Series A Warrants to April 26, 2021 (which is the expiration date of the March Series B Warrants). The March Series A and Series B warrants were liability classified prior to the Exchange because they contained anti-dilution provisions that did not meet the standard definition of anti-dilution provisions. The Company recorded a mark-to-market adjustment to record the March Series A and Series B warrant at their fair values immediately prior to the Exchange and then reclassified the remaining balance of $ 21,858 to equity as a result of the issuance of shares and the removal of the anti-dilution and variable pricing protections in the Exchange. On January 21, 2021, the Company entered into an agreement with an institutional investor, pursuant to which the Company agreed to issue and sell, in an offering (the “January Offering”), warrants exercisable for an aggregate of 294,298 shares of common stock of the Company (the “January Warrants”) at an offering price of $ 4.375 per warrant in exchange for the exercise of the institutional investor’s existing December Series A warrants that were issued to them on December 21, 2020, at an exercise price of $ 41.30 per warrant. The January Warrants have an exercise price of $ 56.00 per share. As compensation to the Placement Agent, in connection with the January Offering, the Company agreed to pay to the Placement Agent a cash fee of 6.0 % of the aggregate gross proceeds raised in the January Offering (including the proceeds relating to the exercise of the December Series A Warrants), plus a management fee equal to 1.0 % of the gross proceeds raised in the January Offering (including the proceeds relating to the exercise of the December Series A Warrants) and reimbursement of certain expenses and legal fees. The Company also issued to designees of the Placement Agent warrants to purchase 17,654 shares of common stock (the “January Placement Agent Warrants”) at an exercise price of $ 70.00 per share. On August 24, 2022, the Company entered into warrant amendment agreements (the “Warrant Amendment Agreements”) with certain holders of the Company’s (i) Series A Warrants to purchase 289,331 shares of common stock with an exercise price of $ 42.00 per share, (ii) Warrants to purchase 294,298 shares of common stock with an exercise price of $ 56.00 per share, (iii) Warrants to purchase 400,815 shares of common stock with an exercise price of $ 31.50 per share, (iv) Warrants to purchase 362,479 shares of common stock with an exercise price of $ 11.20 per share, and (v) Warrants to purchase 3,544,580 shares of common stock with an exercise price of $ 3.25 per share (the “Existing Warrants”). Under the Warrant Amendment Agreements, the Company agreed to amend the Existing Warrants by lowering the exercise price of the Existing Warrants to $ 0.5981 per share. The warrant modification resulted in an increase in the fair value of warrants of $ 1,151 . Subsequent to the warrant amendment, the Company issued 115,000 shares of common stock upon exercise of a portion of the amended warrants for net proceeds of $ 69 . During the year ended December 31, 2021, the Company issued 3,189 shares of common stock upon exercise of the March Series B Warrants for net proceeds of $ 1 and 294,298 shares of common stock upon exercise of the December Series A Warrants for proceeds of $ 12,155 . As of September 30, 2022, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date March Series A Warrants 919 $ 0.35 March 26, 2025 MAM Eagle Lender Warrant 15,060 $ 160.65 May 29, 2027 November Series A Warrants 289,331 $ 0.5981 November 24, 2025 November Placement Warrants 17,357 $ 51.84375 November 24, 2025 December Placement Warrants 17,654 $ 50.96875 December 18, 2025 January Warrants 294,298 $ 0.5981 January 21, 2026 January Placement Warrants 17,654 $ 70.00 January 21, 2026 February Placement Warrants 18,854 $ 70.00 February 8, 2026 May Warrants 400,815 $ 0.5981 June 1, 2027 May Placement Warrants 24,046 $ 37.1875 May 31, 2026 December 2021 Warrants 362,479 $ 0.5981 June 27, 2027 December 2021 Placement Agent 28,996 $ 11.20 December 27, 2026 March 2022 Warrants 78,088 $ 3.25 March 1, 2027 March 2022 Warrants, repriced 3,429,580 $ 0.5981 March 1, 2027 March 2022 Underwriter Warrants 210,526 $ 3.5625 February 24, 2027 May 2022 Warrants 1,646,091 $ 1.09 May 19, 2027 May 2022 Placement Agent 98,765 $ 1.5188 May 17, 2027 August 2022 Series A-1 Warrants 11,819,172 $ 0.525 September 1, 2027 August 2022 Series A-2 Warrants 11,819,172 $ 0.525 October 2, 2023 August 2022 Placement Agent 709,150 $ 0.65625 August 29, 2027 With the exception of the March Series A Warrants to purchase 919 shares of common stock related to the public offering and held by non-participating investors in the Exchange that are liability classified as they contain antidilution provisions that do not meet the standard definition of antidilution provisions, the remaining warrants outstanding are equity classified. The following table summarizes the fair value and the assumptions used for the Black-Scholes option-pricing model for the liability classified warrants. September 30, 2022 Series A Warrants Fair value $ — Expected dividend yield — % Expected volatility 77.76 % Risk-free interest rates 4.25 % Remaining contractual term 2.5 years

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(14) Stock-Based Compensation The Company has adopted the 2019 Plan that allows for the grant of stock options, stock appreciation rights and stock awards for an initial total of 85,714 shares of common stock. On December 1 st of each year, pursuant to the “Evergreen” provision of the 2019 Plan, the number of shares available under the plan shall be increased by an amount equal to 5 % of the outstanding common stock on December 1 st of that year or such lower amount as determined by the Board of Directors. In December 2021, the number of shares available for issuance under the 2019 Plan was increased by 120,605 . The total number of shares authorized for issuance under the 2019 Plan as of September 30, 2022 is 263,167 . As of September 30, 2022, 115,442 shares are available for future grants under the 2019 Plan. Stock Options: Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years . There were no options granted during the nine months ended September 30, 2022. The weighted average grant-date fair value of options awarded to employees during the nine months ended September 30, 2021 was $ 25.39 . Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions: September 30, 2021 Expected option life 5.6 years Expected volatility 75.16 % Risk-free interest rate 0.84 % Expected dividend yield — The following table summarizes Baudax Bio stock option activity during the nine months ended September 30, 2022: Number of Weighted Weighted Balance, December 31, 2021 125,418 $ 76.05 8.6 years Expired/forfeited/cancelled ( 41,980 ) $ 54.41 Balance, September 30, 2022 83,438 $ 86.94 7.7 years Vested 58,987 $ 87.18 7.4 years Vested and expected to vest 83,438 $ 86.94 7.7 years Included in the table above are 3,229 stock options outstanding as of September 30, 2022 that were granted outside of the plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). Restricted Stock Units (RSUs): The following table summarizes Baudax Bio RSUs activity during the nine months ended September 30, 2022: Number of Weighted Balance, December 31, 2021 41,069 $ 63.79 Granted 501,209 0.76 Vested and settled ( 11,909 ) 47.72 Expired/forfeited/cancelled ( 7,155 ) 57.79 Balance, September 30, 2022 523,214 $ 3.86 Expected to vest 508,088 In June 2022, the Company granted 501,209 time-based RSUs, which may be settled in cash, stock, or a combination of cash and stock, solely at the election of the Company. These awards are classified as Other long-term liabilities on the Consolidated Balance Sheet due to insufficient shares available for grant in the 2019 Plan. Included in the table above are 627 time-based RSUs outstanding as of September 30, 2022 that were granted outside of the plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). Stock-Based Compensation Expense: Stock-based compensation expense for the nine months ended September 30, 2022 and 2021 was $ 1,172 and $ 4,132 , respectively, which for the current year also includes expense for the liability classified awards. As of September 30, 2022, there was $ 1,701 of unrecognized compensation expense related to unvested options and time-based RSUs that are expected to vest and will be expensed over a weighted average period of 1.5 years. As of September 30, 2022, there was $ 450 of unrecognized compensation expense related to unvested performance-based RSUs. The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. As of September 30, 2022 , there was no aggregate intrinsic value of the vested and unvested options.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	(15) Related Party Transactions Societal CDMO became a related party to the Company following the Separation. As part of the Separation, the Company entered into a transition services agreement with Societal CDMO , which terminated on December 31, 2020 . Under the transition services agreement, the Company provided certain services to Societal CDMO, each related to corporate functions, which were charged to Societal CDMO. In connection with the Separation, Societal CDMO and Baudax Bio entered into an Employee Matters Agreement. The Employee Matters Agreement allocates liabilities and responsibilities relating to employee compensation and benefits plans and programs and other related matters in connection with the Distribution including, without limitation, the treatment of outstanding Societal CDMO equity awards. In connection with the Separation, Societal CDMO and Baudax Bio entered into a Tax Matters Agreement that governs the parties’ respective rights, responsibilities and obligations with respect to taxes, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes for any tax period ending on or before the Distribution date, as well as tax periods beginning after the Distribution date.

Retirement Plan

Retirement Plan	9 Months Ended
	Sep. 30, 2022
Retirement Benefits [Abstract]
Retirement Plan	(16) Retirement Plan The Company has a voluntary 401(k) Savings Plan (the “401(k) Plan”) in which all employees are eligible to participate. The Company’s policy is to match 100 % of the employee contributions up to a maximum of 5 % of employee compensation. Total Company contributions to the 401(k) plan for the three months ended September 30, 2022 and 2021 were $ 32 and $ 148 , respectively. Total Company contributions to the 401(k) plan for the nine months ended September 30, 2022 and 2021 were $ 373 and $ 569 , respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), for interim financial information and with the instructions of Form 10-Q and Article 10 of Regulation S-X and, therefore, do not include all of the information and notes required by U.S. GAAP for complete annual financial statements. In the opinion of management, the accompanying consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s results for the interim periods. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2021 included in the Company’s Form 10-K.
Use of Estimates	(b) Use of Estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents represents cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired to be cash equivalents. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value because of the changes in interest rates.
Investments	(d) Investments Investments generally consist of government money market funds and commercial paper with maturity of greater than three months when acquired and does not meet the definition of a cash or cash equivalents. The Company has historically classified its entire investment portfolio as available-for-sale debt securities and is carried at fair value with unrealized gains and losses included in comprehensive loss in the consolidated statement of operations and realized gains and losses included in other income/expense, if applicable. The Company uses benchmark inputs and industry standard analytical models to derive the fair value of its commercial paper.
Property and Equipment	(e) Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to seven years for furniture and office equipment; six to ten years for manufacturing equipment; and the shorter of the remaining lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred.
Goodwill and Intangible Assets	(f) Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment model prescribes a one-step method for determining impairment. The one-step quantitative test calculates the amount of goodwill impairment as the excess of a reporting unit’s carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company has one reporting unit. The Company performs its annual goodwill impairment test as of November 30 th , or whenever an event or change in circumstances occurs that would require reassessment of the recoverability of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance of its reporting unit, anticipated changes in industry and market conditions, including recent tax reform, intellectual property protection, and competitive environments. The Company performed an impairment test as of September 30, 2022 after identifying indicators of impairment. There was no impairment to goodwill based on the analysis. The Company’s intangible asset is classified as an asset resulting from R&D activities. The Company determined the useful life of its asset resulting from R&D activities to be approximately 10 years , which is based on the remaining patent life at the time of FDA approval and is being amortized on a straight-line basis. The Company is required to review the carrying value of assets resulting from R&D activities for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of intangible assets is measured by comparing the carrying value of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment recognized is measured by the amount the carrying value of the assets exceeds the fair value of the assets. The Company performed an impairment test as of September 30, 2022 after identifying indicators of impairment, including a decline in share price, the termination of the dedicated commercial team and sustained impacts of COVID-19 on the market. Based on the quantitative analysis an impairment loss of $ 17,746 was recorded as of September 30, 2022 to reduce the carrying value of the intangible asset.
Revenue Recognition	(g) Revenue Recognition The Company sells ANJESO in the U.S. through a single third-party logistics provider (“3PL”), which takes title to and control of the goods, and is considered the customer. The Company recognizes revenue from ANJESO product sales at the point the title to the product is transferred to the customer and the customer obtains control of the product. The transaction price that is recognized as revenue for products includes an estimate of variable consideration for reserves, which result from discounts, returns, chargebacks, rebates, and other allowances that are offered within contracts between the Company and end-user customers, wholesalers, group purchasing organizations and other indirect customers. The Company’s payment terms are generally between thirty to ninety days . The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available. These reserves reflect the Company’s best estimate of the amount of consideration to which the Company is entitled based on the terms of the contracts. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that is considered probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.
Concentration of Credit Risk	(h) Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balance as of September 30, 2022 and December 31, 2021 is compromised solely from transactions with the Company’s 3PL.
Research and Development	(i) Research and Development Research and development costs for the Company’s proprietary products/product candidates are charged to expense as incurred. Research and development expenses consist of internal costs and funds paid to third parties for the provision of services for pre-commercialization and manufacturing scale-up activities, drug development, pre-clinical activities, clinical trials, statistical analysis, report writing and regulatory filing fees and compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development project. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expenses relating to these costs. Upfront and milestone payments made to third parties who perform research and development services on the Company’s behalf are expensed as services are rendered. Costs incurred in obtaining product technology licenses are charged to research and development expense as acquired in-process research and development (“IPR&D”) if the technology licensed has not reached technological feasibility and has no alternative future use.
Stock-Based Awards	(j) Stock-Based Awards Share-based compensation included in the consolidated financial statements is based upon the Baudax Bio, Inc. 2019 Equity Incentive Plan (the “2019 Plan”). The plan includes grants of stock options, time-based vesting restricted stock units (“RSUs”) and performance-based RSUs. The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur. Determining the appropriate fair value of stock options requires the input of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses an average of its peer group’s volatility in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company has never declared or paid cash dividends and has no plans to do so in the foreseeable future, therefore the dividend yield is zero.
Income Taxes	(k) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. Because of the Company’s history of losses as a standalone entity, a full valuation allowance is recorded against deferred tax assets in all periods presented. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.
Net Loss Per Common Share	Net Loss Per Common Share Net loss per common share is computed using the two-class method required due to the participating nature of the Series A Preferred Stock (as defined and discussed in Note 13(b)). Except with respect to voting and conversion, the rights of the holders of the Company’s common stock and the Company’s Series A Preferred Stock are identical. Each class of shares has the same rights to dividends. Although the Preferred Stock are participating securities, such securities do not participate in net losses and therefore do not impact the Company’s net loss per share calculation as of September 30, 2022. Basic net loss per common share is determined by dividing net loss attributable to common shareholders by the weighted average common shares outstanding during the period. Diluted net loss per common share is determined using the weighted average common shares outstanding during the period plus the weighted average number of shares of common shares that would be issued assuming exercise or conversion of all potentially dilutive instruments. Outstanding warrants, common stock options and unvested restricted stock units are excluded from the calculation of diluted net loss per share when their effect would be anti-dilutive. For purposes of calculating basic and diluted loss per common share, the denominator includes the weighted average common shares outstanding, the weighted average common stock equivalents for warrants priced at par value, or $ 0.01 , as the underlying common shares will be issued for little cash consideration and the conditions for the issuance of the underlying common shares are met when such warrants are issued, and, with regard to diluted loss per common share, the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. The following table sets forth the computation of basic and diluted loss per share: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Basic and Diluted Loss Per Share Net loss $ ( 29,205 ) $ ( 16,962 ) $ ( 49,545 ) $ ( 49,203 ) Weighted average common shares 11,836,122 2,411,433 7,685,398 2,112,247 Net loss per share of common stock, $ ( 2.47 ) $ ( 7.03 ) $ ( 6.45 ) $ ( 23.29 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Options and restricted stock units outstanding 606,652 151,955 606,652 151,955 Warrants 31,298,007 1,095,984 31,298,007 1,095,984 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Recent Accounting Pronouncements	(m) Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ,” or ASU 2020-06. ASU 2020-06 simplifies accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. ASU 2020-06 also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company adopted this guidance as of January 1, 2022, using the full retrospective method of adoption. The adoption eliminated the presentation of the beneficial conversion feature on the consolidated statement of operations and had no other material impact to the Company. In May 2021, the FASB issued ASU No. 2021-04, “ Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ,” or ASU 2021-04. ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options, such as warrants, that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years and early adoption is permitted. The Company adopted this guidance as of January 1, 2022, using the prospective method of adoption. This adoption did not have a material impact to the Company or its disclosures. In November 2021, the FASB issued ASU No. 2021-10, “ Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance ,” or ASU 2021-10. ASU 2021-10 requires entities to provide disclosures on government assistance transactions for annual reporting periods. The disclosures include information around the nature of the transaction, the related accounting policies used to account for the transaction, the effect of the transaction on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. ASU 2021-10 is effective for fiscal years beginning after December 15, 2021 and early adoption is permitted. The Company adopted this guidance as of January 1, 2022, using the prospective method of adoption. This adoption did not have a material impact to the Company or its disclosures. Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ,” or ASU 2016-13. ASU 2016-13 requires companies to measure credit losses utilizing a methodology that reflects expected credit losses and requires consideration of a range of reasonable information to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including those interim periods within those fiscal years. The Company is currently assessing the impact of adopting this standard, but based on a preliminary assessment, does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Computation of Basic and Diluted Loss Per Share	The following table sets forth the computation of basic and diluted loss per share: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Basic and Diluted Loss Per Share Net loss $ ( 29,205 ) $ ( 16,962 ) $ ( 49,545 ) $ ( 49,203 ) Weighted average common shares 11,836,122 2,411,433 7,685,398 2,112,247 Net loss per share of common stock, $ ( 2.47 ) $ ( 7.03 ) $ ( 6.45 ) $ ( 23.29 )
Schedule of Anti-Dilutive Securities	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Options and restricted stock units outstanding 606,652 151,955 606,652 151,955 Warrants 31,298,007 1,095,984 31,298,007 1,095,984

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis	The Company has classified assets and liabilities measured at fair value on a recurring basis as follows: Fair value measurements at reporting date using Quoted prices Significant Significant At September 30, 2022: Assets: Cash equivalents (See Note 5) Money market mutual funds $ 2,225 $ — $ — Total cash equivalents $ 2,225 $ — $ — Liabilities: Warrants (See Note 13(c)) $ — $ — $ — Contingent consideration (See Note 12(b)) — — 21,408 $ — $ — $ 21,408 At December 31, 2021: Assets: Cash equivalents (See Note 5) Money market mutual funds $ 10,110 $ — $ — Total cash equivalents $ 10,110 $ — $ — Liabilities: Warrants (See Note 13(c)) $ — $ — $ 7 Contingent consideration (See Note 12(b)) — — 23,862 $ — $ — $ 23,869
Reconciliation of Warrant Liability and Contingent Consideration Measured at Fair Value on Recurring Basis Using Unobservable Inputs	The reconciliation of the warrant liability and contingent consideration measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows: Warrants Contingent Balance at December 31, 2020 $ 65 $ 65,043 Payment of contingent consideration — ( 7,869 ) Remeasurement ( 58 ) ( 33,312 ) Balance at December 31, 2021 $ 7 $ 23,862 Payment of contingent consideration — ( 1,200 ) Remeasurement ( 7 ) ( 1,254 ) Total at September 30, 2022 $ — $ 21,408 Current portion as of September 30, 2022 $ — $ 8,436 Long-term portion as of September 30, 2022 — 12,972

Cash Equivalents (Tables)

Cash Equivalents (Tables)	9 Months Ended
	Sep. 30, 2022
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Summary of Cash Equivalents	The following is a summary of cash equivalents: September 30, 2022 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 2,225 $ — $ — $ 2,225 Total cash equivalents $ 2,225 $ — $ — $ 2,225 December 31, 2021 Amortized Gross Unrealized Estimated Description Cost Gain Loss Fair Value Money market mutual funds $ 10,110 $ — $ — $ 10,110 Total cash equivalents $ 10,110 $ — $ — $ 10,110

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: September 30, 2022 December 31, 2021 Raw materials $ 26 $ 53 Sub-assemblies 4,015 4,656 Finished goods 1,630 645 5,671 5,354 Provision for inventory obsolescence ( 1,194 ) ( 352 ) Inventory $ 4,477 $ 5,002

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: September 30, 2022 December 31, 2021 Building and improvements $ 166 $ 196 Furniture, office and computer equipment 841 952 Manufacturing and laboratory equipment 717 717 Construction in progress 980 4,622 2,704 6,487 Less: accumulated depreciation 1,465 1,472 Property and equipment, net $ 1,239 $ 5,015

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Undiscounted Future Lease Payments for Non-Cancellable Operating Leases	As of September 30, 2022, undiscounted future lease payments for non-cancellable operating leases are as follows: Lease payments Remainder of 2022 $ 111 2023 270 2024 278 2025 278 2026 287 2027 295 Total lease payments 1,519 Less imputed interest ( 678 ) Total operating lease liability $ 841
Schedule of Components Least Cost	As of September 30, 2022, the weighted average remaining lease term was 5 years and the weighted average discount rate was 23 % . The components of the Company’s lease cost were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating lease cost $ 70 $ 79 $ 215 $ 255 Short-term lease cost 33 52 106 130 Total lease cost $ 103 $ 131 $ 321 $ 385

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Balance of Intangible Assets	The following represents the balances of the intangible assets: September 30, 2022 December 31, 2021 Asset resulting from R&D activities $ 26,400 $ 26,400 Accumulated Amortization ( 6,654 ) ( 4,722 ) Impairment loss ( 17,746 ) — Intangible assets, net $ 2,000 $ 21,678
Summary of Future Amortization Expense	As of September 30, 2022, future amortization expense is as follows: Amortization Remainder of 2022 $ 65 2023 261 2024 261 2025 261 2026 261 2027 and thereafter 891 Total $ 2,000

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: September 30, December 31, 2022 2021 Payroll and related costs $ 2,143 $ 3,516 Professional and consulting fees 667 1,071 Other research and development costs 61 157 Interest payable 100 116 Other 348 680 $ 3,319 $ 5,540

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Components of Carrying Value of Debt	The following table summarizes the components of the carrying value of debt: September 30, December 31, 2022 2021 Credit Agreement $ 10,000 $ 10,000 Payment of principal ( 1,112 ) — Unamortized deferred issuance costs ( 969 ) ( 1,583 ) Exit fee accretion 167 114 Total debt $ 8,086 $ 8,531 Current portion $ 5,911 $ 2,222 Long-term portion, net 2,175 6,309

Capital Structure (Tables)

Capital Structure (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Warrants Outstanding to Purchase Shares Common Stock	As of September 30, 2022, the Company had the following warrants outstanding to purchase shares of the Company’s common stock: Number of Shares Exercise Price per Share Expiration Date March Series A Warrants 919 $ 0.35 March 26, 2025 MAM Eagle Lender Warrant 15,060 $ 160.65 May 29, 2027 November Series A Warrants 289,331 $ 0.5981 November 24, 2025 November Placement Warrants 17,357 $ 51.84375 November 24, 2025 December Placement Warrants 17,654 $ 50.96875 December 18, 2025 January Warrants 294,298 $ 0.5981 January 21, 2026 January Placement Warrants 17,654 $ 70.00 January 21, 2026 February Placement Warrants 18,854 $ 70.00 February 8, 2026 May Warrants 400,815 $ 0.5981 June 1, 2027 May Placement Warrants 24,046 $ 37.1875 May 31, 2026 December 2021 Warrants 362,479 $ 0.5981 June 27, 2027 December 2021 Placement Agent 28,996 $ 11.20 December 27, 2026 March 2022 Warrants 78,088 $ 3.25 March 1, 2027 March 2022 Warrants, repriced 3,429,580 $ 0.5981 March 1, 2027 March 2022 Underwriter Warrants 210,526 $ 3.5625 February 24, 2027 May 2022 Warrants 1,646,091 $ 1.09 May 19, 2027 May 2022 Placement Agent 98,765 $ 1.5188 May 17, 2027 August 2022 Series A-1 Warrants 11,819,172 $ 0.525 September 1, 2027 August 2022 Series A-2 Warrants 11,819,172 $ 0.525 October 2, 2023 August 2022 Placement Agent 709,150 $ 0.65625 August 29, 2027
Summary of Fair Value Assumptions Black Scholes Option Pricing Model	The following table summarizes the fair value and the assumptions used for the Black-Scholes option-pricing model for the liability classified warrants. September 30, 2022 Series A Warrants Fair value $ — Expected dividend yield — % Expected volatility 77.76 % Risk-free interest rates 4.25 % Remaining contractual term 2.5 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model	Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions: September 30, 2021 Expected option life 5.6 years Expected volatility 75.16 % Risk-free interest rate 0.84 % Expected dividend yield —
Summary of Stock Option Activity	The following table summarizes Baudax Bio stock option activity during the nine months ended September 30, 2022: Number of Weighted Weighted Balance, December 31, 2021 125,418 $ 76.05 8.6 years Expired/forfeited/cancelled ( 41,980 ) $ 54.41 Balance, September 30, 2022 83,438 $ 86.94 7.7 years Vested 58,987 $ 87.18 7.4 years Vested and expected to vest 83,438 $ 86.94 7.7 years
Summary of RSUs Activity	The following table summarizes Baudax Bio RSUs activity during the nine months ended September 30, 2022: Number of Weighted Balance, December 31, 2021 41,069 $ 63.79 Granted 501,209 0.76 Vested and settled ( 11,909 ) 47.72 Expired/forfeited/cancelled ( 7,155 ) 57.79 Balance, September 30, 2022 523,214 $ 3.86 Expected to vest 508,088

Background - Additional Informa

Background - Additional Information (Details)				9 Months Ended
	Feb. 16, 2022	Nov. 21, 2019 shares	Nov. 15, 2019 shares	Sep. 30, 2022 Segment
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of operating segments | Segment				1
Reverse stock split	1-for-35			On November 3, 2022, shareholders approved an amendment to the Company's Amended and Restated Articles of Incorporation, as amended, which authorized the Board of Directors to effect a reverse stock split of the Company's common stock by a ratio of any whole number between 1-for-5 and 1-for-40.
Separation | Recro
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Right to receive common stock		1
Number of shares held for distribution of new shares			2.5

Development-Stage Risks, Liqu_2

Development-Stage Risks, Liquidity and Going Concern - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Business Developments Risks And Uncertainties Liquidity [Abstract]
Accumulated deficit	$ 181,654	$ 132,089

Summary of Significant Accoun_4

Summary of Significant Accounting Principles - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) Unit $ / shares	May 17, 2022 $ / shares	Dec. 31, 2021 $ / shares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable unit | Unit	1
Goodwill impairment	$ 0
Description of payment terms	The Company’s payment terms are generally between thirty to ninety days.
Impairment loss of Intangible Assets	$ 17,746,000
Common stock, par value | $ / shares	$ 0.01	$ 0.01	$ 0.01
R&D
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible asset, useful life	10 years
Leasehold Improvements
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life	the shorter of the remaining lease term or useful life
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payments term	30 days
Minimum | Furniture and Office Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	3 years
Minimum | Manufacturing Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	6 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Payments term	90 days
Maximum | Furniture and Office Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	7 years
Maximum | Manufacturing Equipment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives	10 years

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Schedule of Computation of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Diluted (Loss) Income Per Share
Net loss	$ (29,205)	$ (7,531)	$ (12,809)	$ (16,962)	$ (15,329)	$ (16,912)	$ (49,545)	$ (49,203)
Weighted average common shares outstanding, basic	11,836,122			2,411,433			7,685,398	2,112,247
Weighted average common shares outstanding, diluted	11,836,122			2,411,433			7,685,398	2,112,247
Net loss per share of common stock, basic	$ (2.47)			$ (7.03)			$ (6.45)	$ (23.29)
Net loss per share of common stock, diluted	$ (2.47)			$ (7.03)			$ (6.45)	$ (23.29)

Summary of Significant Accoun_6

Summary of Significant Accounting Principles - Schedule of Anti-Dilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock Options | Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	606,652	151,955	606,652	151,955
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	31,298,007	1,095,984	31,298,007	1,095,984

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Classification of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents		$ 0
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total cash equivalents	$ 2,225	10,110
Liabilities:
Warrants	0	0
Contingent consideration	0	0
Liabilities	0	0
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Mutual Funds
Assets:
Total cash equivalents	2,225	10,110
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents	0
Liabilities:
Warrants	0	0
Contingent consideration	0	0
Liabilities	0	0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Money Market Mutual Funds
Assets:
Total cash equivalents	0
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)
Assets:
Total cash equivalents	0	0
Total financial assets	21,408
Liabilities:
Warrants	0	7
Contingent consideration	21,408	23,862
Liabilities		23,869
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Money Market Mutual Funds
Assets:
Total cash equivalents	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Reconciliation of Warrant Liability and Contingent Consideration Measured at Fair Value on Recurring Basis Using Unobservable Inputs (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Warrant
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Beginning Balance	$ 7	$ 65
Payment of contingent consideration	0	0
Remeasurement	(7)	(58)
Ending Balance	0	7
Current portion as of September 30, 2022	0
Long-term portion as of September 30, 2022	0
Contingent Consideration
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Beginning Balance	23,862	65,043
Payment of contingent consideration	(1,200)	(7,869)
Remeasurement	(1,254)	(33,312)
Ending Balance	21,408	$ 23,862
Current portion as of September 30, 2022	8,436
Long-term portion as of September 30, 2022	$ 12,972

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Details) $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 01, 2021 USD ($) Milestonepayment	Mar. 31, 2022 USD ($)	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business acquisition, contingent consideration, equal annual milestone payments		$ 1,200
Discount Rate
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-adjusted discount rate			0.3500
Contingent Consideration, Second Component | Alkermes Plc | Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval | Amendment to Purchase and Sale Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45,000
Business acquisition, contingent consideration, number of equal annual milestone payments | Milestonepayment	7
Business acquisition, contingent consideration, equal annual milestone payments	$ 6,400
Contingent Consideration, Fourth Component | Alkermes Plc | Amendment to Purchase and Sale Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum royalty payment percentage			30%
Contingent Consideration, Fourth Component | Alkermes Plc | Amendment to Purchase and Sale Agreement | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Royalty payment percentage			10%
Contingent Consideration, Fourth Component | Alkermes Plc | Amendment to Purchase and Sale Agreement | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Royalty payment percentage			12%

Cash Equivalents - Summary of C

Cash Equivalents - Summary of Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Cash And Cash Equivalents [Line Items]
Amortized Cost	$ 2,225	$ 10,110
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Estimated Fair Value	2,225	10,110
Money Market Mutual Funds
Cash And Cash Equivalents [Line Items]
Amortized Cost	2,225	10,110
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Estimated Fair Value	$ 2,225	$ 10,110

Cash Equivalents - Additional I

Cash Equivalents - Additional Information (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash And Cash Equivalents [Line Items]
Cash equivalents maturity period	1 month	1 month
Minimum
Cash And Cash Equivalents [Line Items]
Cash equivalents maturity period			1 month

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 26	$ 53
Sub-assemblies	4,015	4,656
Finished goods	1,630	645
Inventory, gross	5,671	5,354
Provision for inventory obsolescence	(1,194)	(352)
Inventory	$ 4,477	$ 5,002

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 2,704	$ 6,487
Less: accumulated depreciation	1,465	1,472
Property and equipment, net	1,239	5,015
Buildings and Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	166	196
Furniture, Office and Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	841	952
Manufacturing and Laboratory Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	717	717
Construction in Progress
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 980	$ 4,622

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 39	$ 46	$ 125	$ 195
Impairment loss on property and equipment	$ 3,662	$ 0	$ 3,662	$ 0

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating leases with remaining lease term	5 years
Lessee, operating lease, option to extend	Periods covered by an option to extend the lease were included in the non-cancellable lease term when exercise of the option was determined to be reasonably certain.
Lessee, operating lease, existence of option to extend	true
Operating lease, weighted average remaining term	5 years
Operating lease, weighted average discount rate percent	23%
Cash paid for amounts included in measurement of lease liabilities	$ 254	$ 258

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Future Lease Payments for Non-Cancellable Operating Leases (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
Remainder of 2022	$ 111
2023	270
2024	278
2025	278
2026	287
2027	295
Total lease payments	1,519
Less imputed interest	(678)
Total operating lease liability	$ 841

Leases - Schedule of Components

Leases - Schedule of Components Least Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 70	$ 79	$ 215	$ 255
Short-term lease cost	33	52	106	130
Total lease cost	$ 103	$ 131	$ 321	$ 385

Intangible Assets - Summary of

Intangible Assets - Summary of Balance of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Impairment loss	$ 17,746
Intangible assets, net	2,000
Asset Resulting from R&D Activities
Finite-Lived Intangible Assets [Line Items]
Asset resulting from R&D activities	26,400	$ 26,400
Accumulated Amortization	(6,654)	(4,722)
Impairment loss	(17,746)
Intangible assets, net	$ 2,000	$ 21,678

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 644	$ 644	$ 1,932	$ 1,932
Impairment loss of Intangible Assets	$ 17,746		$ 17,746

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 65
2023	261
2024	261
2025	261
2026	261
2027 and thereafter	891
Intangible assets, net	$ 2,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll and related costs	$ 2,143	$ 3,516
Professional and consulting fees	667	1,071
Other research and development costs	61	157
Interest payable	100	116
Other	348	680
Total accrued expenses and other current liabilities	$ 3,319	$ 5,540

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) $ in Thousands		1 Months Ended	3 Months Ended
	Nov. 30, 2020 USD ($) Employee	Sep. 30, 2022 USD ($) Employee	Mar. 31, 2022 USD ($) Employee
Payables and Accruals [Abstract]
Number of positions reduced | Employee	40	7	66
Severance cost	$ 1,753	$ 241	$ 4,148
Accrued Severance	$ 25	$ 193	$ 1,267

Debt - Schedule of Components o

Debt - Schedule of Components of Carrying Value of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instruments [Abstract]
Credit Agreement	$ 10,000	$ 10,000
Payment of principal	(1,112)	0
Unamortized deferred issuance costs	(969)	(1,583)
Exit fee accretion	167	114
Total debt	8,086	8,531
Current portion of long-term debt, net	5,911	2,222
Long-term debt, net	$ 2,175	$ 6,309

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Oct. 24, 2022

May 29, 2020

Aug. 31, 2022

Nov. 30, 2022

May 31, 2023

Feb. 28, 2023

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2022

Sep. 01, 2022

Aug. 01, 2022

Jun. 30, 2022

May 17, 2022

May 31, 2021

Feb. 08, 2021

Debt Instrument [Line Items]

Proceeds from Issuance of Common Stock

$ 14,270

$ 0

Gain on extinguishment of debt

0

1,553

Term loan, extended expiration date

May 29, 2026

Exercise price of warrants

$ 0.65625

$ 1.5188

$ 29.75

$ 56

Change in warrant valuation

$ (1)

$ (6)

(7)

(47)

Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

$ 50,000

$ 0

$ 0

Line of credit facility, drawn on or before date

May 29, 2025

Term loan, interest rate

13.50%

Term loan, frequency of payments

monthly

Term loan, interest payment period

3 years

EBITDA

$ 10,000

Amortization period

36 months

36 months

Term loan, exit fee due, principal amount advanced by lenders

$ 700

Term loan, exit fees

$ 700

Term loan, payoff period

6 months

Exit fee percentage

2.50%

2.50%

Current outstanding loan balance

$ 250

Financial covenants, minimum liquidity requirement

$ 5,000

Debt issuance costs

1,496

Change in warrant valuation

$ 1,423

Effective interest rate

22.67%

22.67%

Debt issuance cost amortization

$ 193

$ 211

$ 614

$ 633

additional payment of principal

$ 300

principal amount

$ 500

cash covenant

$ 3,000

$ 4,000

$ 4,500

Credit Agreement | Lender

Debt Instrument [Line Items]

amendment fee

200

Credit Agreement | Agent

Debt Instrument [Line Items]

amendment fee

$ 5

Credit Agreement | MAM Eagle Lender, LLC

Debt Instrument [Line Items]

Financial covenants minimum liquidity requirement increased amount

$ 5,000

Percentage of cash used to repay outstanding under the credit agreement

30%

Financial covenants, minimum liquidity requirement

$ 3,000

Credit Agreement | MAM Eagle Lender, LLC | Common Stock

Debt Instrument [Line Items]

Warrants issued to purchase shares of common stock

15,060

Exercise price of warrants

$ 160.65

Warrants exercisable date

May 29, 2027

Credit Agreement | After Third But Prior To Fourth Anniversary of Tranche One, Two, Three, Four or Five Loans

Debt Instrument [Line Items]

Term loan, prepayment of principal percentage

3%

Maximum | Credit Agreement

Debt Instrument [Line Items]

Term loan, exit fee due, percentage of principal amount advanced by lenders

2.50%

Maximum | Credit Agreement | On or Prior To Third Anniversary of Tranche One, Two, Three, Four or Five Loans

Debt Instrument [Line Items]

Term loan, prepayment of principal percentage

5%

Tranche One Loans | Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

$ 10,000

Term Loans | Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

40,000

Tranche Two Loans | Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

$ 5,000

Line of credit facility, drawn on or before date

Aug. 29, 2021

Tranche Two Loans | Minimum | Credit Agreement

Debt Instrument [Line Items]

Net revenue

$ 5,000

Tranche Three Loans | Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

$ 5,000

Line of credit facility, drawn on or before date

Nov. 29, 2021

Tranche Three Loans | Minimum | Credit Agreement

Debt Instrument [Line Items]

Net revenue

$ 10,000

Tranche Four Loans | Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

$ 10,000

Line of credit facility, drawn on or before date

Aug. 29, 2022

Tranche Four Loans | Minimum | Credit Agreement

Debt Instrument [Line Items]

Net revenue

$ 20,000

Tranche Five Loans | Credit Agreement

Debt Instrument [Line Items]

Line of credit facility, maximum principal amount

$ 20,000

Line of credit facility, drawn on or before date

Mar. 01, 2023

Tranche Five Loans | Minimum | Credit Agreement

Debt Instrument [Line Items]

Net revenue

$ 100,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) € in Thousands			1 Months Ended		3 Months Ended			9 Months Ended
	Feb. 01, 2021 USD ($) Milestonepayment	Apr. 10, 2015 USD ($)	Feb. 29, 2020 USD ($) Milestonepayment	Jun. 30, 2017 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)
Supply Commitment [Line Items]
Business acquisition, contingent consideration, equal annual milestone payments					$ 1,200,000
Purchase Commitment
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable								$ 3,419,000
Cornell University | Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Amount of royalty payments due or payable								0
Alkermes Plc | Amendment to Purchase and Sale Agreement
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones								$ 22,629,000
Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage								30%	30%
Alkermes Plc | Amendment to Purchase and Sale Agreement | Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval | Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments | Milestonepayment	7
Business acquisition, contingent consideration, equal annual milestone payments	$ 6,400,000
U.S | Cornell University | Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones				$ 5,000,000
European | Cornell University | Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones				3,000,000
Minimum | Cornell University | Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Cost, Maintenance				70,000
Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								10%	10%
Maximum | Executive Officer
Supply Commitment [Line Items]
Aggregate annual base salaries of employment agreement								$ 927,000
Maximum | Cornell University | Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Cost, Maintenance				$ 125,000
Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								12%	12%
Recro | Alkermes Transaction
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 140,000,000
Recro | Alkermes Transaction | Regulatory Approval and Net Sales Milestones
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 60,000,000
Collaborative arrangements, milestone payments period		7 years
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, First Component
Supply Commitment [Line Items]
Business acquisition contingent consideration, first milestone payment							$ 5,000,000
Business acquisition contingent consideration possible milestone payments						$ 5,000,000
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage								30%	30%
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due, Following Regulatory Approval | Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments			$ 5,000,000
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval | Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments			$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments | Milestonepayment			7
Business acquisition, contingent consideration, equal annual milestone payments			$ 6,400,000
Recro | Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								10%	10%
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								12%	12%
Recro | Dexmedetomidine License Agreement
Supply Commitment [Line Items]
Contingent milestone payments, maximum								$ 20,084,000	€ 20,500
Amount of royalty payments due or payable								$ 0
Recro | Dexmedetomidine License Agreement | Minimum
Supply Commitment [Line Items]
Percentage of royalty payments								10%	10%
Recro | Dexmedetomidine License Agreement | Maximum
Supply Commitment [Line Items]
Percentage of royalty payments								20%	20%
Recro | Fadolmidine License Agreement
Supply Commitment [Line Items]
Amount of royalty payments due or payable								$ 0
Additional contingent milestones payment								$ 11,954,000	€ 12,200
Recro | Fadolmidine License Agreement | Minimum
Supply Commitment [Line Items]
Percentage of royalty payments								10%	10%
Recro | Fadolmidine License Agreement | Maximum
Supply Commitment [Line Items]
Percentage of royalty payments								15%	15%

Capital Structure - Additional

Capital Structure - Additional Information (Details) - USD ($)																					1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended	15 Months Ended
	Sep. 01, 2022	Aug. 24, 2022	May 17, 2022	Mar. 01, 2022	Feb. 16, 2022	Dec. 29, 2021	Dec. 28, 2021	May 31, 2021	May 27, 2021	Feb. 08, 2021	Jan. 21, 2021	Dec. 21, 2020	Dec. 18, 2020	Nov. 24, 2020	Oct. 19, 2020	May 29, 2020	Mar. 26, 2020	Feb. 13, 2020	Jan. 01, 2020	Nov. 21, 2019	Oct. 03, 2022	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	May 27, 2021	Sep. 29, 2022	Sep. 19, 2022	Feb. 28, 2022
Schedule Of Capitalization Equity [Line Items]
Common stock, shares authorized to issue																						190,000,000			190,000,000		190,000,000
Common stock, par value			$ 0.01																			$ 0.01			$ 0.01		$ 0.01
Increase in fair value of warrants																						$ (1,000)		$ (6,000)	$ (7,000)	$ (47,000)
Proceeds from public offering, net of transaction costs																									$ 14,270,000	$ 0
Common stock in public offering																	219,780
Warrant to purchase of common stock			98,765
Reverse stock split					1-for-35																				On November 3, 2022, shareholders approved an amendment to the Company's Amended and Restated Articles of Incorporation, as amended, which authorized the Board of Directors to effect a reverse stock split of the Company's common stock by a ratio of any whole number between 1-for-5 and 1-for-40.
Common stock exercisable price per share				$ 3.25
Proceeds from issuance of common stock underwriting discounts and commissions and offering expenses																	$ 23,085,000
Common stock in direct offering								400,815		314,286			121,428	81,429
Placement agents cash fee percentage			6%										6%	6%											7%
Management fee percentage			1%	1%									1%	1%											1%
Exercise price of warrants	$ 0.65625		$ 1.5188					$ 29.75		$ 56
Preferred stock, shares authorized																						10,000,000			10,000,000		10,000,000
Preferred stock, par value																						$ 0.01			$ 0.01		$ 0.01
Preferred stock, shares issued																						20,003.745			20,003.745		8,289
Preferred stock, shares outstanding																						20,003.745			20,003.745		8,289
Preferred Stock, Voting Rights																							The Preferred Stock have no voting rights, other than the right to vote as a class on certain matters, and each share of Preferred Stock will have the right to cast 3,571 votes per share of Preferred Stock on an amendment to the Company’s Amended and Restated Articles of Incorporation
Common stock, shares issued																						20,003,745			20,003,745		2,807,239
Preferred Stock converted to common stock						34,000
Warrants expiration date	Aug. 29, 2027		May 17, 2027
Public offering price for pre-funded warrant				$ 2,840
Beneficial conversion charge																									$ 2,422,000
Underwriter cash fee	$ 5,065,000		$ 1,720,000	$ 7,000
Management Fee Percentage			1%	1%									1%	1%											1%
Placement Agents Cash Fee Percentage			6%										6%	6%											7%
Proceeds from issuance of warrants				$ 8,791,000			$ 3,658,000
Partially exercised additional warrants purchase																															113,896
MAM Eagle Lender, LLC
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock																15,060
Common stock exercisable price per share																$ 160.65
February Warrants
Schedule Of Capitalization Equity [Line Items]
Proceeds from public offering, net of transaction costs										$ 16,187,000
May Warrants
Schedule Of Capitalization Equity [Line Items]
Proceeds from public offering, net of transaction costs								$ 10,861,000
Warrant to purchase of common stock								400,812
Common stock exercisable price per share								$ 31.50
Exercise price of warrants			$ 1.09																			$ 0.5981			$ 0.5981
December Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants																						0.5981			0.5981
Exercise of Warrants																											294,298
January Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock											294,298
Exercise price of warrants											$ 56											$ 0.5981			$ 0.5981
Offering price of warrant											4.375
March Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock																	219,780
Common stock exercisable price per share																	$ 160.65
September Series A-1 Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock, par value	$ 0.01
Common stock in public offering	7,554,886
Warrant to purchase of common stock	7,554,886
Series B Pre-Funded Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	4,264,286
Common stock exercisable price per share	$ 0.01
Common Stock at a combined offering price	0.515
Exercise price of warrants	$ 0.01
March Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock																	219,780
Common stock exercisable price per share																	$ 113.75
Exercise of Warrants																											3,189
Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	7,554,886																								919
Common Stock at a combined offering price	$ 0.525
Exercise price of warrants	$ 0.525
Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock																									919
Proceeds from issuance of warrants																											$ 1,000
November Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock														289,331
Common stock exercisable price per share														$ 42
November Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Proceeds from public offering, net of transaction costs														$ 10,763,000
Common stock exercisable price per share														$ 0.35
Pre-funded warrants to purchase of common stock														207,902
November Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock														17,357
Exercise price of warrants														$ 51.84375
December 2021 Placement Agent Warrants Member
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock																									28,996
December Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock							362,479						294,298
Common stock exercisable price per share													$ 41.30
Exercise price of warrants							$ 11.20					$ 41.30
Proceeds from issuance of warrants																											$ 12,155,000
December Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Proceeds from public offering, net of transaction costs													$ 10,933,000
Common stock exercisable price per share													$ 0.35
Pre-funded warrants to purchase of common stock													172,869
December Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock													17,654
Common stock exercisable price per share													$ 50.96875
March 2022 Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock				3,508,772
Common stock exercisable price per share				$ 0.01
Common stock in direct offering				1,831,631
Pre-funded warrants to purchase of common stock				1,677,141
Warrants issued to purchase shares of common stock				526,315
Additional Warrants To Purchase Of Common Stock				526,315
Offering price of warrant				$ 2.85
Series A Preferred Stock
Schedule Of Capitalization Equity [Line Items]
Common Stock at a combined offering price			$ 1.215
Preferred stock, par value							$ 0.01
Preferred Stock Value Per Share							100%
Preferred stock, shares issued			1,646,091				42,289.3
Preferred stock if converted to common stock			1,646,091				483,306
Preferred Stock, Convertible, Conversion Price							$ 8.75
Series B Preferred Stock
Schedule Of Capitalization Equity [Line Items]
Common stock, par value																													$ 0.01
Preferred stock, par value																														$ 0.01
Preferred stock, shares issued																						20,003.745			20,003.745
Preferred Stock, Voting Rights																					1,000,000
February Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock										18,854
Exercise price of warrants										$ 70
February Placement Agent Warrants | February Warrants
Schedule Of Capitalization Equity [Line Items]
Percentage of cash fee on gross proceeds										6%
Percentage of management fee on gross proceeds										1%
May Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock								24,046
Exercise price of warrants								$ 37.1875
May Placement Agent Warrants | May Warrants
Schedule Of Capitalization Equity [Line Items]
Management fee percentage								1%
Percentage of cash fee on gross proceeds								6%
Management Fee Percentage								1%
Underwriter Warrants
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants				$ 3.5625
Underwriter Warrant Purchase of Common Stock				210,526
Placement Agent
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants											$ 70
Placement Agent | December Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Percentage of cash fee on gross proceeds												6%
Percentage of management fee on gross proceeds												1%
Placement Agent | January Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock											17,654
ATM Facility
Schedule Of Capitalization Equity [Line Items]
Stock Issued During Period, Shares, New Issues									12,628
Common stock, par value																		$ 0.01
Proceeds from sales agreement																												$ 3,612,000
Proceeds from public offering, net of transaction costs																		$ 25,000,000
Paid sales commission																												3%
Warrant Exchange Agreements
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued															33,908
Warrant Exchange Agreements | March Series A and Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Reclassification to equity upon warrant exchange															$ 21,858,000
Warrant Exchange Agreements | March Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock, par value															$ 0.35
Warrants expiration date															Apr. 26, 2021
Warrant Exchange Agreements | March Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock, par value															$ 0.35
Warrants expiration date															Apr. 26, 2021
Warrant Exchange Agreements | Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrants issued to purchase shares of common stock															0.0057
Warrant Exchange Agreements | Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Warrants issued to purchase shares of common stock															0.0057
Warrant Amendment Agreements
Schedule Of Capitalization Equity [Line Items]
Increase in fair value of warrants		$ 1,151,000
Exercise of Warrants		115,000
Proceeds from issuance of warrants		$ 69,000
Warrant Amendment Agreements | Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		289,331
Exercise price of warrants		$ 42
Warrant Amendment Agreements | Existing Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		3,544,580
Common stock exercisable price per share		$ 0.5981
Exercise price of warrants		$ 3.25
Warrant Amendment Agreements | Series A Warrants One
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		294,298
Exercise price of warrants		$ 56
Warrant Amendment Agreements | Series A Warrants Two
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		400,815
Exercise price of warrants		$ 31.50
Warrant Amendment Agreements | Series A Warrants Three
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		362,479
Exercise price of warrants		$ 11.20
Recro
Schedule Of Capitalization Equity [Line Items]
Stock Issued During Period, Shares, New Issues																			1,311	268,473
Recro | Separation
Schedule Of Capitalization Equity [Line Items]
Right to receive common stock																				1
H.C. Wainwright & Co., LLC
Schedule Of Capitalization Equity [Line Items]
Placement agents cash fee percentage	7%		7%
Management fee percentage	1%
Warrants issued to purchase shares of common stock	709,150
Management Fee Percentage	1%
Placement Agents Cash Fee Percentage	7%		7%

Capital Structure - Schedule of

Capital Structure - Schedule of Warrants Outstanding to Purchase Shares Common Stock Liability (Details) - $ / shares	Sep. 30, 2022	Sep. 01, 2022	May 17, 2022	May 31, 2021	Feb. 08, 2021	Jan. 21, 2021
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants		$ 0.65625	$ 1.5188	$ 29.75	$ 56
March Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	919
Exercise price of warrants	$ 0.35
Warrants expiration date	Mar. 26, 2025
March 2022 Warrants [Member]
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	78,088
Exercise price of warrants	$ 3.25
Warrants expiration date	Mar. 01, 2027
March 2022 Warrants, repriced [Member]
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	3,429,580
Exercise price of warrants	$ 0.5981
Warrants expiration date	Mar. 01, 2027
MAM Eagle Lender Warrant
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	15,060
Exercise price of warrants	$ 160.65
Warrants expiration date	May 29, 2027
November Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	289,331
Exercise price of warrants	$ 0.5981
Warrants expiration date	Nov. 24, 2025
December Series A Warrant [Member]
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	362,479
Exercise price of warrants	$ 0.5981
Warrants expiration date	Jun. 27, 2027
November Placement Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	17,357
Exercise price of warrants	$ 51.84375
Warrants expiration date	Nov. 24, 2025
December Placement Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	17,654
Exercise price of warrants	$ 50.96875
Warrants expiration date	Dec. 18, 2025
January Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	294,298
Exercise price of warrants	$ 0.5981					$ 56
Warrants expiration date	Jan. 21, 2026
January Placement Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	17,654
Exercise price of warrants	$ 70
Warrants expiration date	Jan. 21, 2026
February Placements Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	18,854
Exercise price of warrants	$ 70
Warrants expiration date	Feb. 08, 2026
May Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	400,815
Exercise price of warrants	$ 0.5981		$ 1.09
Warrants expiration date	Jun. 01, 2027
May Placements Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	24,046
Exercise price of warrants	$ 37.1875
Warrants expiration date	May 31, 2026
December 2021 Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	28,996
Exercise price of warrants	$ 11.20
Warrants expiration date	Dec. 27, 2026
Underwriter Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	210,526
Exercise price of warrants	$ 3.5625
Warrants expiration date	Feb. 24, 2027
May 2022 Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	1,646,091
Exercise price of warrants	$ 1.09
Warrants expiration date	May 19, 2027
May 2022 Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	98,765
Exercise price of warrants	$ 1.5188
Warrants expiration date	May 17, 2027
August 2022 Series A-1 Warrants [Member]
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	11,819,172
Exercise price of warrants	$ 0.525
Warrants expiration date	Sep. 01, 2027
August 2022 Series A-2 Warrants [Member]
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	11,819,172
Exercise price of warrants	$ 0.525
Warrants expiration date	Oct. 02, 2023
August 2022 Placement Agent Warrants [Member]
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	709,150
Exercise price of warrants	$ 0.65625
Warrants expiration date	Aug. 29, 2027

Capital Structure - Summary of

Capital Structure - Summary of Fair Value Assumptions Black Scholes Option Pricing Model (Details) - Series A Warrants $ in Thousands	Sep. 30, 2022 USD ($)
Schedule Of Capitalization Equity [Line Items]
Fair value	$ 0
Remaining contractual term	2 years 6 months
Expected Volatility
Schedule Of Capitalization Equity [Line Items]
Fair value measurement warrant inputs	77.76
Risk Free Interest Rates
Schedule Of Capitalization Equity [Line Items]
Fair value measurement warrant inputs	4.25

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Nov. 11, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 1,172,000	$ 4,132,000
Aggregate intrinsic value of vested options	0
Aggregate intrinsic value of unvested options	$ 0
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercisable period	10 years
Stock options vest period	4 years
Weighted average grant-date fair value of the options awarded to employees		$ 25.39
Time-based RSUs Granted Outside Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Time-based RSU, granted	627
Stock Options And Time-based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to unvested options and time-based RSUs, expected to vest	$ 1,701,000
Time Based Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Time-based RSU, granted	501,209
Unrecognized compensation expense related to unvested options, weighted average period	1 year 6 months
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant	263,167		85,714
Percentage of outstanding common stock	5%
Increase in share per "Evergreen" provision	120,605
Shares available for future grants	115,442
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period	3,229
Unrecognized compensation expense related to unvested options and time-based RSUs, expected to vest	$ 450,000

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model (Details) - Stock Options	9 Months Ended
	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected option life	5 years 7 months 6 days
Expected volatility	75.16%
Risk-free interest rate	0.84%
Expected dividend yield	0%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of shares, beginning balance	125,418
Number of shares, Expired/forfeited/cancelled	(41,980)
Number of shares, ending balance	83,438	125,418
Number of shares, Vested	58,987
Number of shares, Vested and expected to vest	83,438
Weighted average exercise price, beginning balance	$ 76.05
Weighted average exercise price, Expired/forfeited/cancelled	54.41
Weighted average exercise price, ending balance	86.94	$ 76.05
Weighted average exercise price, Vested	87.18
Weighted average exercise price, Vested and expected to vest	$ 86.94
Weighted average remaining contractual life	7 years 8 months 12 days	8 years 7 months 6 days
Weighted average remaining contractual life, Vested	7 years 4 months 24 days
Weighted average remaining contractual life, Vested and expected to vest	7 years 8 months 12 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted Stock Units	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, beginning balance	41,069
Number of shares, Granted	501,209
Number of shares, Vested and settled	(11,909)
Number of shares, Expired/forfeited/cancelled	(7,155)
Number of shares, ending balance	523,214
Number of shares, Expected to vest	508,088
Weighted average grant date fair value, beginning balance | $ / shares	$ 63.79
Weighted average grant date fair value, Granted | $ / shares	0.76
Weighted average grant date fair value, vested and settled | $ / shares	47.72
Weighted average grant date fair value, Expired/forfeited/cancelled | $ / shares	57.79
Weighted average grant date fair value, ending balance | $ / shares	$ 3.86

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Societal CDMO
Related Party Transaction [Line Items]
Transition services agreement termination date	Dec. 31, 2020

Retirement Plan - Additional In

Retirement Plan - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Retirement Benefits [Abstract]
Percentage of company's matching contribution with respect to each participant's contribution			100%
Company matching contributions to maximum employees eligible compensation			5%
Total company contributions to 401 (k) plan	$ 32	$ 148	$ 373	$ 569